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Abstract
The body of work presented in this thesis is related to the development and efficacy
of new and multimodal treatments for cancer. The relative cytotoxicity as well as
selectivity of such modalities is assessed through various cell assay techniques (including clonogenic assay) by involving separate and co-cultured cell experiments.
Two cancer cell lines are used in these studies, the very radioresistant 9L cell line
(gliosarcoma brain cancer model) and the Michigan Cancer Foundation-7 (MCF7)
cell line (invasive breast ductal carcinoma model). In addition, and where relevant,
the Madin-Darby Canine Kidney (MDCK) cell line was also studied as an example
of a non-cancerous cell in vitro model for compound, drug and/or nanoparticle exposure as well as multimodal treatment response.

The first treatment investigated involves improving the efficacy of radiotherapy. The
radiosensitisation enhancement effect is studied through the inclusion of bromodeoxyuridine compounds (BrUdR) and tantalum pentoxide nanostructured particles
(Ta2 O5 NSPs) in combination with 5-Fluorouracil (5-FU) subjected to kilovoltage
(kV) and megavoltage (MV) X-ray treatment beams.

For kV X-ray irradiation, BrUdR and Ta2 O5 NSPs were irradiated in their optimum operating voltage of 125 kVp and 150 kVp, respectively. With a Z of 35 and
10 µM molecular mass concentration, BrUdR has shown to radiosensitise in both
kV and MV radiation fields, achieving the sensitisation calculated at 10% clonogenic
survival fraction (SER10% ) of 1.58 and 1.53, respectively. Ta2 O5 NSPs with a higher
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Z of 73 and molecular mass concentration of 113 µM, achieved SER10% of 1.03 and
1.29 in kV and 10 MV respectively. These results highlight the importance of the
subcellular localisation of the high-Z element as well as their distribution within the
whole target volume in order to maximise the radiation dose enhancement in the
clinically relevant irradiated energy of 10 MV.

Additionally, the combination of 5-FU (0.01 µM) with either BrUdR or Ta2 O5 NSPs
was found to increase the radiosensitisation, yielding a very significant SER10% of
2.11 for 5-FU + BrUdR under kV irradiation, clearly demonstrating one of the
main aims of this thesis, that the synergistic effect can be achieved by combining a
superficial radiotherapy treatment with 5-FU+BrUdR. At the 10 MV, the SER10%
obtained for 5-FU + BrUdR was 1.61, and 1.35 for 5-FU+Ta2 O5 NSPs. Despite the
less significant SER10% increase from the respective results achieved using the high
Z material alone, their survival curves exhibited absolutely no characteristic shoulder with increasing treatment dose. This suggests an increase in the complex lethal
damage. This significant finding confirmed one thesis hypothesis that the effect of
5-FU is dependent on the presence of high-Z to radiosensitise but is independent of
their Z number and their location to the DNA.

The second treatment investigated involves assessing and improving the efficacy on
modulated electro-hyperthermia (mEHT). In particular, the efficiency of the mEHT
treatment technology using the 9L, MCF-7, and MDCK cell lines. The selectivity
feature of the mEHT was not clearly demonstrated in this study. The survival fraction of 9L cells for radiation alone and its combination with mEHT were (35 ± 1)
% and (13 ± 1) % respectively. Whereas the survival fraction results for MDCK
showed a marginal contribution of mEHT pre-treatment when used in combination
with radiation. This is observed in the survival fractions obtained for radiation alone
and its combination with mEHT of (5.4 ± 0.2) % and (4.4 ± 0.2) % respectively.
Despite the supra-additive effect achieved on the 9L cells and a negligible effect
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achieved for the MDCK cells in the combined mEHT and radiation treatment, the
selectivity could not be underlined. This is because of the negligible effect result
obtained for MCF-7 cells under the same condition.

The mechanism of the mEHT treatment could not be identified in this study. The
Ta2 O5 NSPs and gold (Au) nanoparticles utilised in this mEHT mechanism investigation indicated that the hyperthermia feature of the mEHT is not the main
mechanism of killing under the exposure of radiation.
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Chapter 1
Introduction
1.1

Background

Making a tumour more sensitive to radiotherapy to maximise the absorbed dose in
malignant cells is a primary goal of combining chemotherapy and radiation therapy.
Additionally, introducing a high atomic number (Z) material to the malignant cells
has also been found to enhance the effect of the ionising radiation dose to the target [Ant+15].

Radiation therapy alone can destroy cancer cells by inducing significant damage
(directly or indirectly) to their deoxyribonucleic acid (DNA). In many cases the
damage to the DNA is short-lived as the DNA is naturally repaired. Extensive
research has been invested into improving the effectiveness of radiotherapy. This includes the work into developing other state-of-the-art techniques that allow for geometrically better targeting lesions. These techniques include three-dimensional conformal radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, stereotactic radiation therapy and proton therapy [Mac+07; Nut+11;
Wat+11]. As well as the physical approach, this is to introduce high Z enhancement/nanoparticles into the lesions [Pig+03; Rah+09]. Moreover, in some instances,
the radiation can pose a different effect by increasing the expression of cancer-driving
genes such as the epidermal growth factor receptor, thus resulting in the resistance
1
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to radiation [Bro13]. Due to the aforementioned limitations of radiation treatment,
chemotherapy utilising 5-FU for example is considered.

1.2

Thesis overview

Improvements in radiation dose delivery to ensure a more efficient killing of cancer
cells has been the focus of many researchers in the field. The investigation into
assessing and improving the therapeutic effectiveness of cancer treatment technology
with the underlying aim of improving local tumour control are the accent of this
thesis work. The objective of this thesis work is to gain a better understanding of
two cancer treatments and how to improve the treatment outcome through better
therapeutic effectiveness with:
1. A halogenated pyrimidine (i.e. Bromodeoxyuridine) in combination with an
anticancer drug (i.e. 5-Fluorouracil) to increase in the irradiation sensitisation
effects using external X-ray radiation beam.
2. A nontoxic high-Z nanostructured particles of Ta2 O5 are introduced as a means
of enhancing the radiation treatment in combination with an anticancer drug
(i.e. 5-Fluorouracil) using external X-ray radiation beam.
3. A study into the efficiency of the modulated electro-hyperthermia technology
utilising a healthy cells line and two cancerous cells lines.

Chapter 2
Literature Review
2.1

Introduction

Cancer is a diverse group of hundreds of diseases in which the body’s abnormal
cells begin to multiply out of control. The abnormal cells can invade and damage
the tissue around them, and spread to other parts of the body, causing further
damage and eventually death. In the past year, this amounted to 138,321 people in
Australia being diagnosed with cancer [HA; 17]. Unfortunately, although the science
and technology of cancer treatments is continually advancing, we still have a long
way to go. Currently, the overall 5-years survival of cancer patients, compared with
the general population, is only 69%, although this does vary widely depending on
the type of cancer [HA; 17]. In 2018, 48,586 people in Australia died of cancer [HA;
17]. There is, therefore, clearly a huge need for dramatic improvements in cancer
prevention and cure. The focus of this thesis is to investigate into the different
treatment modalities in radiation oncology, each with the ultimate goal of improving
patient outcomes.

3
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2.2

Principle of Radiation Therapy

2.2.1

Introduction to Radiation Therapy

4

Radiation therapy uses high-energy electromagnetic radiation to shrink tumours and
kill cancer cells [DLR08]. This treatment modality primarily aims is to eliminate
cells in tumour by irradiation with the smallest damage to the surrounding normal
tissues. The radiation may be delivered by either external-beam radiation therapy
or internal radiation therapy (e.g., brachytherapy).

Brachytherapy refer to the treatment in which radioactive material is placed near or
into the cancer region [Maz05]. This method allows a higher radiation dose delivery
to the target tumour and less radiation damage to the healthy tissue. Even though
brachytherapy came into clinical practice in the 1970s, researchers are continuing to
work on overcoming the challenges of brachytherapy in order to optimise this cancer
treatment technique, for example, the technically inability to accurately implant the
radioactive sources.

The use of external beam radiotherapy is the predominant treatment modality use
today in cancer treatment. The external radiation delivers high-energy radiation
beam via linear accelerators (LINAC). The radiation beam penetrates the tissues
and delivers the radiation dose deep in the areas where the cancer resides. The
LINAC is constantly developing to provide other state-of-the-art techniques that
allow significantly reduce side effects while improving the ability to deliver radiation to the tumour target [Mac+07; Nut+11; Wat+11]. These techniques include
three-dimensional conformal radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and stereotactic radiation therapy. All of which
have the same sequel and that is to increase accuracy in the delivery of radiation
to the target tumour tissue, sparing the surrounding healthy tissues. However,
these techniques can only do so much if the tumour cells are radiation resistant in
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characteristics. For this reason, there is constant on-going research in the area of
nanostructured materials and drug develpment to improve the treatment efficacy of
the cancerous cells. Upon successful development the research often continues to
evolve, moving into the in vitro experimental stage of testing.

2.2.2

Therapeutic Ratio

The therapeutic ratio (or sometimes referred to as the safety window) in radiation
therapy, is a way of quantitatively describing the part of the treatment that destroys
the tumour cells without causing intolerable damage to nearby normal tissues. It
is defined by the comparison of dose-response relationships between tumours and
normal tissues (see Figure 2.1). Different types of tumours possess different levels
of sensitivity to radiation. As such, tumours that are radiation resistant will result
in the two dose-response curves being very close. That is, the radiation dose required to control these radiation resistant tumours is close to the tolerance levels
of surrounding healthy tissues. In clinical practice, the approach to maximise the
therapeutic ratio is to manipulate the radiation treatment design. For example,
delivering radiation beams from different angles at which the tumour is located at
the crossfire. By doing so, the radiation dose delivery to the healthy surrounding
tissues is minimised. Using in vitro cell models, this thesis work explores different
means to sensitise the radiation resistant tumour cells. This can potentially increase
the effectiveness of the clinical approach. As such, hopefully further increasing the
separation between the dose-response curves, which increases the therapeutic ratio
of the dose response.

2.2.3

Physical effect of Radiation Therapy

2.2.3.1

Ionising Radiation

Radiotherapy is commonly used in the treatment of a malignant tumour and incorporates a beam of ionising radiation. The radiation, be it charged particulate or
uncharged, deposits energy into the medium it penetrates. This is quantified by the
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Figure 2.1: The therapeutic ratio describe the relationship between tumour
control probability and the probability of normal tissue complication [Hua15].

absorbed dose (energy absorbed per unit mass) that is measured in “Grays” (1 Gy=
1 Joule/kilogram). Ionising radiations include a variety of highly energetic radiations, all with the ability to eject electrons from the atoms in the matter through
which they pass. This leads to the production of positive and negative charged ions,
hence the term ionising radiations. The relative probabilities of radiation interaction
with matter of different atomic number (e.g., malignant cells loaded or not with a
high-Z atom) as a function of photon energy is as shown in Figure 2.2.

Figure 2.2: Relative cross sections for photoelectric, Compton, and pair production interaction of photons with matter as a function of photon energy and
atomic number of media [CK13].
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Interaction of Ionising Radiation

A linear accelerator (LINAC) uses high radio-frequency electromagnetic wave power
by microwave technology to accelerate the electron to nearly the speed of light before striking tungsten target [Kha94]. As the electrons decelerate, a production of
bremsstrahlung radiation (X-rays) is emitted with a spectrum ranging from zero to
their maximum kinetic energy. The radiation beam quality is expressed in terms of
the highest-energy photons as a function of the electron accelerating voltage, kVp
(kilovolts peak) or MV (megavoltage) [MRW00]. The external X-ray beam typical
of radiotherapy utilises electron accelerating potentials in the range of 50kVp up
to 25MV [Att08; Kha94]. Consequently, the energy range of the generated X-ray
photons implies the relevant interactions of X-rays photons with tissue are the photoelectric effect, the Compton effect, and pair production [Att08; MKH07].

Photoelectric Effect

A photoelectric interaction is an interaction between a photon and an inner atomic
shell electron of the medium. This interaction results in this incident photon being
completely absorbed by the electron resulting in the ejection of this electron known
as a photoelectron.
The probability of the photoelectric absorption, τ , depends strongly on the
atomic number of the attenuation medium (Z), the energy of the incident photon
(E):
τ
Z3
= 3,
ρ
E

(2.1)

where ρ is the physical density (g/cm3 ) of the attenuating medium. Therefore, photoelectric absorption is the predominant interaction for low-energy incident photons
(< 0.03 MeV) and become more important as the atomic number increases. This Z
dependence of the photoelectric effect can be used to improve the therapeutic effect
of radiation, explained in later sections.
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Auger Effects

The Auger effect is a result of the photoelectric effect. The event is caused by
electron transitions that are initiated when low energy X-ray photons interact with
the target atoms and eject electron(s) [Hof96]. The transition of an electron from
an outer shell to the vacancy in the inner-shell will release characteristic X-rays (see
Figure 2.3) or low-energy Auger electrons (Auger process). The Auger process dominates when no X-ray is emitted (Figure 2.3). At the time the outer-shell electron
falls to the inner-shell, it transfers its surplus energy (Esurplus = Ephoton − EBinding ) to
another atomic electron, which is then ejected from an outer shell. This release of
electron(s) from the atom is provided with sufficient kinetic energy to account collectively for the excess energy. These Auger electrons inherit energy that contributes
to the absorbed dose [Att08]. The probability of either of these photoelectric interactions is highly dependent upon both the photo energy and the atomic number of
the targeted elements (as mentioned in previous sections).

Figure 2.3: Auger electron process [LPD16]
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Compton Effect

Compton X-ray interactions dominate for higher energies than the photoelectric
effect. Incidentally for very low Z materials, the Compton effect dominates at all
high energies. The incident X-ray photon interacts with an electron of an atom,
resulting in some energy being scattered, and some being transferred to the electron. The energy given to the orbital electron is sufficient to its ejection from the
atom. Compton interaction probability depends primarily on the electron density
(proportional to Z/A, where A is the atomic mass number) [Ken15], and is almost independent of atomic number [Att08; Kha94]. The interaction probability decreases
gradually with increasing photon energy.

Pair Production

Pair production occurs when the energy of X-ray photon is greater than 1.02 MeV.
The photon interacts with the atomic nucleus, creating electron-positron pair each
have a rest mass equivalent to 0.51 MeV. Energy in excess of this 1.02 MeV is distributed to the two particles as kinetic energy. The probability of pair production
increases with increasing photon energy (approximately ≥ 5 MeV) and increases
approximately as Z 2 [Kha94].

2.2.4

Radiobiological Effect on Radiation Therapy

2.2.4.1

Radiation Damage within the Cell

The biological effects of ionising radiation (IR) depend on the quality and the dose
of radiation, and the cell type. However, it is also strongly dependent on details of
how the energy is deposited at the microscopic level. This is described by the average energy transfer per unit length of the track- linear energy transfer (LET). LET
represents the energy lost per unit distance as an ionisation particle travels through
a material and it is used to quantify the effects of IR on biological specimens. Bi-
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ological effects of radiation can result from both direct and indirect action. The
path from irradiation of the cells to the induction of a biological specimen consists
of several complex steps, as shown in Figure 2.4.

The subsequent chemical phase ionisation processes predominantly involve wa-

Figure 2.4: Direct and indirect actions of radiation. The structure of DNA is
shown schematically [HG06].

ter molecules as water accounts for approximately 85% of the weight of most cells
(see [Mur+06; Bus+03] for more details). When ionizing radiation passes through
living tissue, electrons are removed from neutral water molecules to produce H2 O+
ions, given by the following equation

H2 O

radiation

→

H2 O+ · + e− ,

(2.2)

where H2 O+ · is a free radical ion (the dot representing an unpaired electron) that is
very unstable and extremely reactive. This ion radical decays to forms the hydroxyl
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free radical by reacting with another water molecule

H2 O+ + H2 O → H3 O+ + OH·,

(2.3)

where OH· is hydroxyl radical (with the dot representing an unpaired electron).

The main products of the radiolysis, or radiation-induced breakdown, of water as
shown are hydrogen and hydroxyl free radicals. This highly reactive hydroxyl radical
that diffuses into deoxyribonucleic acid (DNA) molecule induces damage by breaking
the chemical bonds of the DNA base-pair bonds. Consequently, this often leads to
the damage in the biologically important molecules such as the cellular membrane,
enzymes, and the DNA. [Mit+00]. Hence, the hydroxyl free radicals represent the
most important species formed during radiolysis on LET.

2.2.4.2

Relative Biological Effectiveness

Biological response to ionising radiation is described in terms of the relative biological effectiveness (RBE). Different radiation particles (as mentioned in previous
section) have different magnitudes of RBE, and is characterised by LET. Therefore,
the ionisation densities between different radiation sources will vary widely. RBE is
defined as the ratio of biological effectiveness of one type of ionising radiation relative to another, given the same amount of absorbed energy [CK13; Law71]. This
allows comparison of a test radiation with a standard radiation. The formulation is

RBE =

Dose of Standard Radiation
,
Dose of Test Radiation

for the same amount of biological damage.
(2.4)

Historically, the standard radiation for determining RBE was

60

Co gamma rays.

However nowadays, it is typical to use 250 kVp as it is more readily available.
The effect of the LET on RBE is shown in Figure 2.5. The LET of approximately 100 keV/µM is optimal in terms of producing biological effect [HG06]. This
peak in RBE occurs when the average separation between ionisation event is ap-
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proximate the same as the diameter of the DNA double helix (2nm), giving the
passing of a single particle the highest probability of causing a double-strand break.
The decrease in the RBE with higher LET (as seen in the fall-off in the curve) is
due to more ionisation events occurring than needed. This results in the reduced
biological effect per radiation dose. The determining of RBE is not straightforward.
It has strong dependency on the cell and tissue type, the end point used (e.g. 10%
survival in colony formation), and the radiation dose delivered per fraction.

Figure 2.5: Effect of LET on RBE [HG06].

2.2.5

Irradiation Methods of Delivery

Conventional photon therapy provided using LINACs and occasionally orthovoltage are a known form of low LET. Therapies such as heavy ion beam therapy,
microbeam radiation therapy and neutron therapy are classified as high LET forms
of radiation. Consequently, these other therapies possess a higher RBE and in turn,
provide a lower oxygen enhancement ratio (OER). This means that the effect of
tumour hypoxia (hypoxic tumour cells are relatively resistant to radiation) is of less
significance when irradiating with high LET radiation than when irradiating with
low LET radiation. This effectiveness of radiation for various sources of clinical
radiation beams is displayed in Figure 2.6.
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Figure 2.6: The effectiveness of radiation based on RBE and OER [Sih10].

2.3
2.3.1

Biological Principle of Radiosensitivity
Introduction

Exposure of biological tissues to ionising radiation immediately leads to the ionisation and excitation of their atoms. They react with other nearby molecules,
thereby transferring chemical damage to them (see previous section 2.2.4.1); these
free-radical processes are usually complete within a millisecond under ideal physiological conditions [TDW05]. All components of the cell will be damaged in this way.
This includes proteins, enzymes, and membrane components. However, such components are present in vast numbers in every cell and damage to a few of them may
have very minimal impact on the cells functional integrity; the cell can regenerate to
combat any compromise made to its survival. But there is one cellular component
which is almost unique regardless of other characteristics: DNA [TDW05].
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Cellular DNA target

DNA is a very long double-helix molecule consisting of a repeated sequence of bases.
Each DNA strand is composed of:
i. a purine base (adenine, guanine) or a pyrimidine base (cytosine, thymine);
ii. a molecule of sugar (deoxyribose) connected to the base;
iii. a molecule of phosphoric acid connected to the sugar.
The DNA molecule is composed of two complementary strands links by hydrogen
bonds between the bases [TDW05]. Thymine (T) on one strand can only be paired
to adenine (A) on the other strand and guanine (G) on one strand can only be
linked to cytosine (C) on the other strand. The DNA molecule is diagrammatically
presented in the form of an upright ladder that is comprised of the two strands
whose bases are linked by hydrogen bonds (see Figures 2.7 and 2.8).

Figure 2.7: Illustrate of the DNA strand assembly: the bases are attached to
the sugars which are themselves connected by phosphates, the alternation sugarphosphate forming the backbone of the strand. In the case of the RNA the
thymidine base is replaced by uracil and the deoxyribose sugar is replaced by
ribose [Alb+02].
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Figure 2.8: Details of the bonding between strands showing the hydrogen bonds
which join complementary bases [Alb+02].

Groups of bases form the genes that contain instructions for proteins and thus for
all aspects of cellular function. Therefore, the successful functioning of a cell and
guaranteed transmission of the genetic information contained in it to its progeny
depend on the maintenance of the integrity of each DNA molecule [TDW05]. There
is usually some duplication of genes, but even so there is a serious risk that radiation
damage may lead to the loss (or modification) of some genes and thus the loss of
specific functions (some of which may be essential for survival) [TDW05]. This is
the reason why DNA is the most vulnerable part of a cell to radiation damage.

2.3.3

Radiation-Induced Cell Death

DNA molecules are the central targets for biological damage induced by ionising radiation. Ionising radiation therapy interacts with cells by liberating electrons from
the atoms, rendering those atoms positively charged. The liberated electrons sequentially interact with water molecules, leading to the formation of free radicals.
These free radicals is the catalyse of various types of lesions on the DNA.
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Cell Death

Irradiation can kill cells via two main mechanisms. Programming cell death (apoptosis) is one of the mechanisms. The process is mediated by an intracellular program,
which leads to morphological changes in the cells and fragmentation of DNA. The
second mechanism is by interrupting reproduction of the cells. Ionising radiation
often prevents the continual multiplication of cells. The higher the radiation dose
applied, the more effective this mechanism of cell kills [Sán+94]. The cells that are
able to continue to divide after exposure to radiation form clones, which represents
the basis of the clonogenic assay (discussed in the following section). Investigation
of radiation-induced cell death in terms of a loss of proliferating capacity is used in
this study.

2.3.4

Dose-Effect Relationship

Cell Survival Curves

Cells that do not lose their reproductive integrity form colonies. Colonies that
contained more than 50 cells are considered as survivors (i.e., clonogenic cells) and
the others are not. These cells that have the capability to survive and continue to
multiply form the basis of evaluating the effect of radiation on different cell types.
The radiation sensitivity of cells can be expressed with cell survival curves. A cell
survival curve describes the relationship between the radiation dose and the proportion of cells that survive. It is a graphical representation of survival fraction on
a logarithmic scale versus dose of ionising radiation on a linear scale. Clonogenic
cell survival, or its converse, cell death is defined for the proliferating cells as loss
of the capacity for sustained proliferation [HG06]. This is denoted as the endpoint
measured with cells cultured in vitro.
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Linear-Quadratic Model

Linear-quadratic model is used to describe the cell survival curve [CL73]. The
model is a function of radiation dose D with two components (α and β) to cell kill
by radiation
F (D) = αD + βD2 .

(2.5)

The α (with units Gy−1 ) component describes the initial slope of the survival curve,
representing a single-hit killing kinetics. The β (with units Gy−2 ) describes the
quadratic component of cell killing, and relates to cell-kill as a result of multi-hit.
Radiation-induced cell killing depends on these two components. From this model,
the survival fraction S for the cells yields
S(D)
2
= e−αD−βD ,
S(0)

(2.6)

where S(D) is the survival fraction at dose D, S(0) is the cell survival fraction at a
dose equal to 0.

Of a particular interest is when αD = βD2 (i.e., the curviness of cell survival plot),
as shown in Figure 2.9. That is when the linear and quadratic contributions to cell
killing are equal at the dose of radiation (in Gy). Mathematically, this implies that
one solution curve D is equal to the ratio

α
.
β

As α and β constants are unique to

the cell type, their ratio must be taken to give a global comparison. High

α
β

inform

a characteristic of cell with little repair capability (e.g., tumour cells), whilst low
α
β

present a characteristic of high repair potential (e.g., late responding normal tis-

sue). Tumours are known to exhibit

α
β

ratio of 10 Gy and late responding tissues 3

Gy [MKH07]. Simplistically, the α component represents the intrinsic radiosensitivity of the target cells and the β component represents the extent to which damage
can be repaired.
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Figure 2.9: Survival Curve [LLC16]

2.3.5

Mechanism of Cell Killing

2.3.5.1

Types of DNA Damage

DNA molecules are constantly exposed to endogenous and exogenous sources, which
produce thousands of lesions. The DNA lesions can be spontaneous or induced by
a particular cellular product or chemical compound.

Endogenous

Endogenous source of DNA damage is predominantly involves chemical modification of nitrogenous bases and disruption of the helical structure of the DNA (for
example, see Figure 2.10) [Lod+95]. The links between a nucleobase and a pentose
sugar is unstable and prone to breakage, consequential in the spontaneous base loss
in DNA (approximately 104 bases per cell per day) [Lin93]. The rate of DNA base
loss is greatly accelerated by heat and low pH. This is due to the higher susceptibility of their nitrogen atom (N9, for glutamine) to nucleophilic attack (a chemical
process at which an electron-rich atom or nucleus actively forms a new bond with
an electron-poor atom or positive ion), causing the purine bases to have a higher
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hydrolysed rate than pyrimidines bases. Other types of endogenous DNA damage
include deamination events [Kav+07], replication errors (can causes mismatch of
bases) and reactive oxygen species.

Exogenous

To date, there are innumerable exogenous agents and compound that cause damage
to the DNA. Nevertheless, the major exogenous sources of DNA damage are ultraviolet rays and ionising radiation. These two forms of radiation can induce the same
types of damage effect as endogenous source. Ultraviolet radiation can produce both
free radicals and results in formation of dimers. The formation for dimmer (deamination events) occurs when two adjacent bases of a single strand become joined.
This formation interrupts the replication of DNA at that site. Ionising radiation
fundamentally causes double-strand break (DSB) but also cause single-strand break
(SSB) at lower irradiation doses. It can as well induce replication and transcriptional
errors leading to cancer [Lod+95].

Figure 2.10: Types of DNA damage [HEN14].

2.3.5.2

Radiation-Induced Clustered DNA Damage

The main types of lesions induced in DNA are single-strand break (occurs at lower
irradiation doses), double-strand break, cross-links between two components of the
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DNA or between DNA and proteins, and other damage to the bases constituting
the DNA [Hut61; Mou+75]. The proportion of these damage types leads to the
differences in radiosensitivity and RBE [Bar94].

Low-LET radiation produces SSB, which is easily repaired. However, higher radiation dose of low-LET can produce SSB in close proximity to each other in both
strands (DSB) (get figure maybe from sianne), as also observed with radiation of
relatively high-LET. The DNA double-strand break is generally accepted to be the
most important lesions of cell death.

Clustered DNA Damage

Radiation causes clusters of lesions along the track of the ionising particles [Cad+12;
EOL11]. This idea of clustered DNA damage is introduced by Ward [War81] as local multiple damaged sites (LMDS). It is defined as two or more lesions within 1-2
helical turns of DNA by a single radiation track. LMDS are caused by the nonuniform ionisation radiation events followed the passage of the secondary electrons
through matter and the generation of radicals that attack DNA [War81]. Radiation induces these non-DSB clustered DNA damage sites have been recently shown
to have yields four to eight times that of direct DSB, comprising by low doses of
ionising radiation [Sut+00; Sut+02].

2.3.6

DNA Damage Repair in Irradiated Cells

Cells have evolved multiple repair mechanisms to counter the damage to DNA depending on the type of damage inflicted. As such, most radiation induced DNA
damage can normally be repaired. When a cell encounters damage that is more
difficult to repair (i.e. clustered DNA damage), the DNA damage response mechanism delays cell-cycle progression. This is to provide more time for repair of the
lesions. In this study, the complex DNA damage (DSB and non-DSB clustered DNA
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damage) is the most important lesion under exposure to radiation, and so only the
double-strand DNA damage response is discussed.

DNA DSB Repair

Cell repairing of DNA DSB is by means of one of two mechanisms nonhomologous end-joining or homologous recombination.

Nonhomologous end joining (NHEJ) is a simple repairing mechanism by means of
joining the two broken ends. It is also the most frequent way of repair. This process takes place in three stages: tethering; end processing; and ligation. Tethering
stage involve recognition of DSB which is initiated by a protein complex (the MRN
complex), which acts to bring together the DNA broken strands together. The protein heterodimer Ku 70/80 recognises the double-strand break and recruits other
proteins involved in repair [DeF+02]. End processing is the next followed stage, by
which damaged or mismatched nucleotides are resynthesised by the MRN complex.
The completing stage in NHEJ is the ligation (or rejoining of the two ends). Ku
70/80 heterodimer interacts with DNA ligase IV to complete the ligation [Kao+06].
NHEJ is susceptible to errors compared to homologous recombination, a more complex process that repairs double-strand breaks with perfect fidelity [Alb+02].

Homologous recombination (HR) depends on a homologous chromosome to provide
a complementary template for DNA damage repairing [Alb+02]. Its process also
begins with recognition of the DSB by the MRN complex. Nucleotides are remove
from the 5’ end on the nucleotide sugar-ring (see Figure 2.11) of the DSB [MS09].
This removal site creates a 3’ end overhang, which is then coated with extensive
proteins to allows the undertaken of strand invasion [Kao+06]. The coated 3 end
interacts with a sister chromatid to find and invade a complementary DNA sequence
that is not broken. Strand invasion results in a DNA double helix consisting of two
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strands that were initially part of two different DNA molecules (see Figure 2.12).
The completion double-stranded DNA repair is then followed by either the doublestrand break repair (DSBR) or the synthesis-dependent strand annealing (SDSA).
Briefly, the DSBR results in the formation of two independent DNA strands [MSB07]
and SDSA is simply an alignment of the repeat sequence on either side of the break,
which allows annealing at the repeated sequence [LA09].

Figure 2.11: A furanose (sugar-ring) molecule with carbon atoms labeled using
standard notation. The 5’ is upstream; the 3’ is downstream. DNA and RNA are
synthesized in the 5’ to 3’ direction [NEU08].

Figure 2.12: During the process of meiosis, homologous chromosomes can recombine and produce new combinations of genes in the daughter cells [Emw08].
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NHEJ is the only DSB repair pathway that is active throughout the cell cycle [Mao+08].
HR is particularly sensitive in late S and G2 phases of the cell cycle. Rothkamm et
al. [Rot+03] first showed the importance of these two repairing process within the
phases of the cell cycle to the radioresistivity of the cell.

2.3.7

Cell Growth Arrest

Cell Cycle

The cell cycle is the series of events that follow the cell growth and development.
The four phases of the cell cycle are the pre-DNA synthesis phase (G1 ), the DNA
synthesis phase (S), the pre-DNA mitosis phase (G2 ), and mitosis (M). There exists
an exit passage at the G1 phase that allows the slow or non-divide cells to leave the
cell cycle indefinitely (G0 ).

Cell Radiosensitivity

The radiosensitivity of a cell varies with both the cell type (rate of proliferation)
and phase of the cell cycle, as shown in Figure 4.15. S-phase cells are relatively
more radioresistant than G1 , G2 and M phase cells [HG06]. Therefore the DNA
repair pathways will demonstrate a cell-cycle phases specific characteristic, which
consequently require different enzymes to act upon the different DNA lesions. For
instance, as mentioned previously, HR is predominantly sensitive in the S- phase.

DNA integrity checkpoints

DNA damages will often lead to arrest at cell cycle checkpoint. Cell-cycle progression is controlled at three most important checkpoints.
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Figure 2.13: Diagram of the cell cycle [Tim16].

The first checkpoint is at the G1 /S transition. This is primary the initiation point to
ensure that cell do not divide under unfavourable conditions. The conditions include
growth factors, correct size, has adequate energy reserve to divide, and inspection
for DNA damage. Once the cell passes this checkpoint, it becomes irreversibly
committed to the division process. Second is the S phase checkpoint. The display
of radioresistant DNA synthesis in cells is due to specific genes deficiency [HY09].
Therefore, the radiation-induced damages cells in this phase are able to be repair
more easily. Third, are the G2 /M checkpoints. Low-doses radiation (e.g. approximately 1 Gy) doses activate the early G2 checkpoint, which affect the cell cycle
progression at the end of G2 into mitosis phase. Post-radiation activate the double
checkpoint. It causes a delay in G2 phase before entry into mitosis [WB09]. Exposure to high-dose radiation could have cells permanently arrested at G2 /M.

The DNA damage response pathways can activate cell cycle checkpoint to arrest
the cell either transiently or permanently. Cells that could not progress through
and complete the cell cycle events may lead to cell death.
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Chemotherapy is the utilisation of anti-cancer drugs to weaken, eventually killing
them on its own or making other treatment modality more efficient. The drug(s)
used in chemotherapy can consist of only one or multiple drugs delivered at the
same time. Moreover, this treatment can also be administered before or after, or
concurrent with radiation therapy. One drug choice employed in chemotherapy such
as the fluorouracil (5-FU) has been proven to be clinically effective. In particular,
this drug has been found to specifically target the thymidylate synthase (TS) of
the folate cycle of DNA [LHJ03]. This in turn causes the cell to develop cytotoxic
efficiency [LHJ03].

To date, chemoradiotherapy with antimetabolites has become the standard therapy
for the treatment of a wide range of solid tumours, such as esophageal carcinoma,
head and neck cancer, as well as rectal cancer. Chemoradiotherapy is a marriage
between chemotherapy and radiotherapy, and the 5-FU drug is one of the most
commonly used anticancer drugs, especially where the local regional control is often
required [HSH06]. An antimetabolite has the capability to inhibit the post-radiation
damage repair [Leh14]. It was hypothesised that the DNA synthesis and repair share
common pathways [Leh14]. Agents that target the radioresistant S-phase of the cell
cycle such as 5-FU, may therefore be effective in preventing the generation of growth
of the tumour cell [Leh14].

The DNA damage response pathways can activate cell cycle checkpoint to arrest
the cell either transiently or permanently. Cells that could not progress through
and complete the cell cycle events may lead to cell death.
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Inhibition of the Repair Processes in Cells with
Chemotherapeutic Agent

Chemotherapeutic agents and drugs are selectively employed in the treatment of
cancer to eliminate malignant cells. The incorporation of chemical compounds as
anticancer drugs acts as an agent to destroy cancer cells by inhibiting them from
multiplying. Most anticancer drugs act by disrupting the function of DNA and are
classed as cytotoxic.

The selection of drug is based on valid scientific evidence and the folate cycle of
DNA. The folate cycle (see Figure 2.14) has a vital role in the nucleotide synthesis,
which is the basic building block of nuclei acids. Examples of this are DNA and
ribonucleic acid (RNA). In general, drugs that can be utilised must have the structure of analogue folic acid, as this allows them to integrate into the folate cycle.
Intuitively, this includes the TS. Through polyglutamation (i.e., the process of becoming more acidic in structure), the selected drug would demonstrate similar characteristics to that of TS, causing the cell to develop cytotoxic efficiency [Cha+85].
Consequently, this makes 5-FU the desired chemotherapeutic agent that specifically
targets the TS. The chemical mechanism of the 5-FU is discussed in the following
section.

2.4.3

Chemotherapeutic Agents

2.4.3.1

Cellular Uptake of 5-FU

5-FU was designed, synthesized and proven by Heidelberger [Hei+57] to possess antitumour capabilities. The structure of 5-FU resembles the pyrimidine bases, which
allows itself to be integrated into nucleoside metabolism, causing the suppression
of the RNA and the DNA replication [Ooy+07].There are two main anabolic route
of 5-FU that give rise to active metabolites [MM02]. One of the routes of the 5FU metabolism results in the formation of 5-FUTP. 5-FUs shape is similar to that
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Figure 2.14: Folate cycle [NC13].

of uracil thus allowing the fluoronucleotide to be recognised by RNA polymerases
during transcription. This leads to the incorporation of 5-FU in RNA replication
enzymes. However, 5-FU does not perform the same chemistry as uracil, it creates
disturbance in RNA synthesis which hinder the growth of cancerous cells [MM02;
Asc+92]. The second route of 5-FU activation is by the formation of 5-FdUMP in
the anabolic route [MM02]. FdUMP inhibits the TS, which subsequently suppresses
DNA synthesis. It interrupts the action of this enzyme, blocks synthesis of the
pyrimidine thymidine, which is a nucleoside required for DNA replication and repair,
leading to cancerous cells death [MM02; Ooy+07].

2.4.3.2

Cellular Uptake of Methotrexate

The first drug ever used in chemotherapy against cancer is methotrexate (MTX),
and its target is the enzyme after TS, dihydrofolate reductase (DHFR). MTX has
been identified as an antifolate inhibitor of DHFR and also acts as a catalyst in the
conversion of dihydrofolate (DHF) to tetrahydrofolate (THF) which is essential for
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DNA synthesis (Figure 2.14). Similar to 5-FU, MTX exerts its chemotherapeutic
effect by being able to counteract and compete with folic acid in cancer cells resulting
in folic acid deficiency in the cells and causing their death. It performs this by
competitively inhibiting DHFR, an enzyme that is critical to produce folate cofactors
which are essential in the synthesis of both DNA and RNA.

2.4.3.3

Fluorodex

Fluorodex is a novel emerging drug that has a parenteral 5-FU and folinic acid
formulations (termed FUdex) [Loc+09; Stu+11]. It was synthesised to overcome
the accepted incompatibility of 5-FU and folinic acid, which would be of significant
clinical benefit as it will ultimately improve the patients quality of life [Stu+11]. The
potential success of this novel drug would classed it as the ‘first in class’ anti-cancer
drug-biomodulator [Stu+11].

2.4.4

Limitation of Chemoradiotherapy

Given a mild to moderate therapeutic effectiveness in chemoradiotherapy with antimetabolites, investigation into improving the therapeutic effectiveness of radiation
via radiation enhancers have been the focus of many researchers in this field. Research has long demonstrated that the delivered dose to the target was increased
when a high Z material was in the targeted zone [Spi49]. Hence, a comprehensive
breakthrough for local treatment and radiotherapy is dependent on the possibility
of depositing a high quantity of energy within the tumour mass.

Moreover, despite a plethora of research reporting the effectiveness of the 5-FU
drug, in clinical treatment, the response rates are modest due to its high cytotoxicity and less therapeutic efficacy in the treatment of advanced disease (Llson DH,
2008). Taken together, the 5-FU drug, is therefore, often delivered in conjunction
with other agents during radiation treatment to amplify its antitumour effect. The
other agents considered for this study are high Z radiation enhancers (e.g., nanopar-
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ticles).

2.5

Introduction to Nanotechnology and
Nanomedicine

Nanotechnology is a vastly expanding technology with numerous and diverse applications due to the unique properties of the nanoparticles. The most distinguishable
characteristic of the nanoparticles is that the properties that these particles possess
are often of no resemblance to that of the equivalent bulk material [BPR07]. The
significant reduction in size associated with the nanoparticles leads to a high particle
number per unit mass as well as a much greater surface area (see Figure 2.15). This
growth in the surface area-to-volume ratio markedly contributes to an increase in
the chemical reactivity [BPR07]. That is, the movement from micro to nanoscale
had been found to increase the reactivity by 1000 times [BPR07]. This increase of
reactivity with matter at the nanoscale level makes nanoparticles the perfect radiosensitiser candidate. An example of this is the standard use of Gold nanoparticles
in the radiobiological dose enhancement [Rah+09; Hai+08].

Figure 2.15: Surface area per unit mass as a function of particle diameter,
distinguishing the large reactive surface areas for nanoscale particle [BPR07].

Leading onto nanoparticles that serve as radiosensitisers are Hafnium oxide
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nanoparticles (NBTXR3) and Activation and Guidance of Irradiation by X-Ray
(AGuIX). NBTXR3 has demonstrated its radiosensitising effects on tumour cells,
and as well has led to increased delay in tumour growth. NBTXR3 is currently
being evaluated clinically as radiosensitiser in phase I and phase II trials (Phase I
and Phase II: NCT02721056). AGuIX is a novel nanoparticle that has been demonstrated its effectiveness as theranostic and radiosensitiser agent in preclinical studies [Ver+19]. This nanoparticle has been accepted in clinical trials in association
with radiotherapy (Phase 1: NCT03308604 and Phase II: NCT04094077).

2.5.1

Gold Nanoparticles

As a radiosensitiser, gold nanoparticles (hereon referred to as Au NPs) has shown
promise due to its high Z (Z = 79) value, effective targeting and biocompatibility [Con+05; LCD08; MUF80; Mel+83; Nor+97; Shu+05]. These characteristics
allow for greater radiation energy absorption and can selectively target tumour cells
which in turn spares normal tissue [Ans+05; Nii+04].

Hainfeld et al. [HSS04] were the first to demonstrate the ability of Au NPs to enhance the effect of x-ray radiation. They showed this by demonstrating substantial
improvements in tumour control in mice receiving kilovoltage radiotherapy minutes
after the injection of Au NPs [HSS04]. Additionally, the study demonstrates that
these Au NPs exhibit preferential tumour targeting [HSS04]. The results prompted
a range of theoretical and experimental studies of the radiosensitizing effects of Au
NPs. There is a broad consensus that Au NPs can significantly sensitize cells to ionizing radiation both in vitro (with reported dose enhancement factors in the order
of 10 to 100%) and in vivo. This has prompted Phase I clinical trials (for example,
NCT02755870). Moreover, this has been demonstrated for a range of different radiation types, including keV photons from brachytherapy and kilovoltage (kV) sources,
megavoltage (MV) photons, MeV electrons and heavy charged particles [HSS04;
Kim+12; Liu+08; Wol+15; Zha+08], suggesting broad clinical applicability. Al-
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though this dose enhancement effect is observed when using Au NPs, its limitations
to radiosensitisation include the dependency on the cell geometries and its distribution with respect to the cell nucleus [Sun+17]. Nevertheless, its main limitation
is the high cost of the material and formulation. This then has provided much
motivation to explore other nanomaterials and different treatment modalities.

2.6

Introduction to Hyperthermia

Following on from the need to experiment with alternative treatment methods, one
that is considered in this thesis is in the area of hyperthermia. Hyperthermia first
found its origins in the middle of the 19th century where rare instances of spontaneous regression of tumours were observed in patients suffering from a very high
fever. This led to an attempt to create an artificial fever to increase the temperature at the tumour site. However, this method of treatment was deemed extremely
complex due to the technical difficulties and lack of a biological rationale, which
ultimately resulted in the development of this treatment method being halted.

The advancement in the technique of heating and measurement of temperature
around the 1960s paved way for the study of the biological effect of hyperthermia
to be revived. The initial study was carried out utilising the scientific methodology
employed in radiobiology.

Localising hyperthermia to the treatment target site can be achieved via different techniques depending on the thickness and depth of the treatment target. For
example, utilising infra-red radiation or direct contact via a temperature conducting
material are methods applicable for experiments with small-sized animals or in vitro
cell cultured samples. For clinical use however, localised hyperthermia is commonly
required at a deeper and larger volume. This can be achieved via diathermy techniques using electric currents, electromagnetic waves or ultrasound.
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Capacitive radiofrequency (RF) hyperthermia uses an alternative electric field to
heat areas of the body and has been widely used in conventional practice in Korea
and Japan. In Germany, it is most often used in complimentary clinics. A frequency of 13.56 MHz is often used as it provides reasonable penetration into the
body without the need for electromagnetic shielding of the device and its public
availability.

2.6.1

Radiosensitisation by Hyperthermia

The application of hyperthermia has been established as a complementary treatment
to most of the traditional treatment modalities [Iss08; HS14]. It has been shown to
provide synergies with most of the traditional treatment modalities, which include
radiation therapy [HS14; BE74; SRD79]. Conventional hyperthermia combined with
radiotherapy has been reported to improve clinical response, local control and the
survival in randomised trials for patients with breast, head and neck cancers, skin
melanoma and glioblastoma multiform [VA94; Sne+98]. However, it should be emphasized that there are many factors which can affect the overall complete response
rate in patients [Ver+96; Dat+90]. The efficiency of radiotherapy is oxygen dependent. This means those tumours that are severely hypoxic are more resistant
to radiation treatment. Therefore, one of hyperthermia’s role is to increase blood
perfusion (oxygenation) of the tumour through the increased temperatures [Ole95;
DLA16]. Hyperthermia is also more effective in hypoxic conditions. This subsequently increases sensitisation to radiation ionisation.

2.6.2

Limitation of Hyperthermia and Hyperthermia Radiotherapy

Despite conventional hyperthermia technology being used since the early 1900s, benefit is not widely accepted in conventional clinical practice. This is mainly attributed
to hyperthermia’s limitation in transferring heat to deep tissue and its ability to focus this transfer of heat energy only on malignant cells [Jon+06]. Other limitations
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of hyperthermia include the limited correlation between temperature and the heat
energy that is being delivered. This makes it problematic to control and supply
sufficient energy to the target tissue.

The positive impact of hyperthermia in combination with radiotherapy is evident in
clinical results [SRD79; Sne+98; Ver+96]. However, there are disappointing clinical
trials as well [ON83; Ema+96]. The controversial clinical results and unexplained
underlying mechanisms including risks and safety issues of hyperthermia are its
challenges in oncology.

2.7

Principle of Modulated ElectroHyperthermia

2.7.1

Introduction to mEHT

Modulated electro-hyperthermia (mEHT) has been an applied method in oncology
since 1989 [SSS10]. It has a long history with a large number of documented case
reports and clinical trials [SSS10]. However, the clinical trials are dominantly retrospective and there are only a few controlled randomised clinical trials that were
evidence-based. Furthermore, there exist challenges to objectively evaluate the clinical results of mEHT treatment [SS13]. Thus, there is much progression to be made
before it is accepted as a conventional treatment by the wider medical community
either as standalone or a complementary of treatment with the gold standard (e.g.,
radiotherapy).

2.7.2

Principle of mEHT Mechanism

mEHT is a method of using non-ionising electromagnetic radiation to energies the
treatment target. The root of mEHT is the delivery of charges into the target by
an external electrode to energies and cause damage to target cellular [SSS10]. The
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target tissue is integrated to be a part of the closed electric circuit, which allows
for direct controlled by the circuit parameters. The tumour represents impedance
in the circuit, directly dependent on the generating electromagnetic source. The
radiofrequency (RF) source is applied to provide the current in this mEHT method.
This RF-current passes through the skin surface over the target volume and selects a lower impedance (resistivity) path. Accordingly, the impedance of the target drives the current densities in its tissue [SSS10]. The malignant cells have a
lower impedance compare to the healthy cells because of their higher conductivity.
This starts the mEHT self-selective process of energy concentration on the malignant cell. Subsequently, it selects and attack membrane rafts through using the
temperature gradient and the beta-dispersion to charge cellular membrane orients
proteins [SSS10]. This results in the death of malignant cells. The extracellular
heating and special fractal modulation (time fractal fluctuation) of the carrying frequency of 13.56 MHz is to enhanced selectivity of power deposition in malignant
tissue [SSS10]. In fact, it is the special fractal modulation of the carrier frequency
that is claimed to give the enhanced selectivity of the tumour cells in the target
and allows the use of much lower applied power levels than other similar devices.
It is predominantly this special fractal modulation that differentiates mEHT from
conventional capacitive radiofrequency (RF) hyperthermia [SSS10].

Its laboratory and clinical results excellently show its advantages; however, there
is very limited evidence in the pre-clinical setting. In particular, the lack of rudimentary knowledge for in vitro purposes. It is the fundamental work in vitro that has
the power to microscope the mechanism of cancer treatment. The aforementioned
lack of research for in vitro applications has left the knowledge of its mechanisms
still under investigation even today.
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mEHT Selectivity on the Tumour

The differences in the conductivity and permittivity (i.e., complex dielectric constant) at the applied 13.56 MHz frequency between the healthy and tumour tissues
are due to the structural and functional deviations of the of the malignant tissue
from its counterpart healthy tissue. The biological disparities results in the malignant tissue having a lower impedance. It is these differences in conductivity and
permittivity that the RF-current can selectively distinguish malignant tissue from
the surrounding healthy tissue environment. The main factors that attribute to a
lower impedance on the malignant tissue are:
• Malignant tissue often requires a higher molecular and ionic transport within
the cellular system. This leads to an overall higher ionic concentration which
results in a lower impedance.
• For tumours in the advanced stages, the blood perfusion in the area is more
than its counterpart healthy tissue environment [FTK98]. This further contributes to a lower impedance [FTK98].
• The water component of the substance that encapsulates the malignant cell
is more disordered [OBC03]. This reduces hydronium ion mobility, which
simultaneously increase the mobility of all other ions in the substance.
• Most tumours possess a lower pH than their environment [Par+09].
• Tumours often have a higher metabolic rate than their healthy counterpart [SFS82;
FS81]. This higher metabolic rate subsequently leads to increase the temperature of the tumour which is known to also decrease the impedance of the
tissue [Ger99].
The lower impedance of a region simply equates to a higher conductivity of the same
region, which means more currents will be flowing through the region and thus more
absorbed energy into the volume of the tumour.
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mEHT Selectivity Enhancement via Special Fractal
Modulation

mEHT selectively causes high energy absorption in the nanoscopic range of the malignant cell membrane [SAM13]. This is possible because of the special delivery
process of the energy which involves the use of fractal modulation or time-fractal
modulation [SAM13; SSS10].

The 13.5 MHz is just like other carrier frequency; it serves only as a medium for the
information transfer. For mEHT, this information is the applied energy. mEHT applies fractal modulation (Figure 2.16b) to the carrier frequency (see Figure 2.16a).
The time-fractal signal modulates the carrier frequency amplitude (as seen in Figure 2.16c) and the result is a modulated signal (Figure 2.16d). The modulated
carrier frequency is embedded with vital characteristics that allow an enhanced
target selective capability [SAM13]. In theory, the healthy cells will remain undisturbed provided the modulation signal is synchronized to the dynamic fluctuations
of healthy tissue. Thus, malignant cells will be isolated and be heated up by the
selectively absorbed energy brought about by mEHT.

2.8

Optimisation of radiation therapy with high
Z materials

The concept of using high-Z materials to increase the dose given to a tumour during
radiation therapy was revealed more than 20 years ago when iodine was shown by
Matsudaira et al. to sensitize cultured cells [MUF80; Mel+83].

2.8.1

Bromodeoxyuridine as a Radiosensitiser

Bromodeoxyuridine (BrUdR) is a halogenated pyrimidine that is known to sensitise
the cells to ionising radiation [SHN68; DH65]. It is a classic radiosensitiser used
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Figure 2.16: The process of amplitude modulation. The carrier signal in a)
combined with the modulated signal b) results in a modulated signal within the
frame of the modulator c). The final modulated carrier frequency signal is then
given by d) [SAM13].

in therapy with radiation displaying low LET such as x-rays and gamma-rays. Its
role in radiosensitisation is not clear but its presence in the DNA strand renders
the DNA to be more susceptible to radiation. This, in turn, yields in an enhanced
radiosensitivity of the carrier cells. The hypothesis among studies documented that
the incorporation of BrUdR produced denser ionisation pathways/tracks that causes
a clustered DNA damage along with radicals that were formed by the low-LET
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ionising radiation [Eps+93]. This clustered DNA damage lead to a higher RBE,
making it as effective as high-LET radiation.

2.8.2

Tantalum Oxide Nanostructured Particles

Tantalum was discovered to be a biomaterial earning its place in a long history of
applications in medicine. Its popularity in application arises from the fact that other
metals used at the time were cytotoxic. The undesirable reaction (i.e., the cytoxicity) from other metals was found to be the result of an electro- chemical process
known as corrosion. Thus, tantalum became a solid candidate when a corrosion
resistant metal was required. One of favourable features of tantalum is it allows the
formation of a thin, impenetrable oxide film on the metal surface that prohibits access of damaging substances and hence does not initiate inflammatory/foreign body
reactions. Therefore, oxidation of tantalum permits the metal to have a biocompatibility. In addition to tantalum being resistant to corrosion and its relatively
nontoxic nature, it is also known to be chemically stable and highly ductile, which
leads to its widely used in clinical applications as a part of radiographic markers,
implants, artificial joints and stents [98].

Currently, the use of tantalum pentoxide nanostructured particles (Ta2 O5 NSPs) as
a radio-sensitiser-based high-mass energy absorption coefficient is novel in the field
of nanomedicine. Ta2 O5 NSPs has been experimentally shown to cause cell sensitisation in a higher energy MV radiation [Bro+14]. This study found that when the
9L cells containing Ta2 O5 NSPs was exposed to the radiation, a higher degree of
damage (due to dose enhancement) is observed in comparison to the irradiated cells
that were not treated by the Ta2 O5 NSPs.

2.8.3

Biological Effect of Radiation-Induced Auger Cascades

In an Auger process, X-ray irradiation can also produce significant enhancement
of the energy deposition events around photoabsorption sites. X-ray irradiation
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provides considerably larger photoabsorption cross-sections of inner-shell electrons
than those of the outer shell electrons [Kob+10]. Moreover, higher-Z elements give a
larger total photoabsorption than those of lower-Z elements [HGD93]. Thus, X-ray
photoabsorption produce not only photoelectrons, but it also induces Auger effects
at the photoabsorption site. Therefore, the presence of high-Z elements in X-ray
photon irradiation will enhance radiobiological effects as efficiently as high LET radiation.

The Auger electrons can be highly radiotoxic, primarily due to their high-LET
particle behaviour. Their range is very short, often similar to the width of a DNA
molecule (i.e., approximately 10 µm), so when they are produced from atoms in or
immediately adjacent to intra-nuclear DNA, they mainly contribute to cell death.
They are produced in greatest abundance at energies slightly at the K-absorption
edge of the absorbing atom (i.e., Bromide), and are frequently produced copiously
following an exposure to a single X-ray. Such events are referred to as Auger cascades.

One of the major aims of this project is to increase the dose delivery to the tumour target through the use of stable radiosensitiser. This is attributed to the fact
that BrUdR and Ta2 O5 NSPs is a highly absorbing radiation agent in tumours (i.e.,
a high-Z element) that has a photo-absorption cross-section via the radiobiological
effects of Auger electrons released as the consequence of photoelectric effect (induced
by external X-ray beams).

Chapter 3
Materials and Methods
3.1

Materials

3.1.1

Cell Lines

The rat gliosarcoma (9L) cell line and the Madin Darby Cancine Kidney (MDCK)
cell line were obtained from the European Collection of Cell Cultures. The 9L cell
line was distributed by Westmead Children Hospital, Australia. The MDCK cell
line was distributed by Sigma-Aldrich, Australia. The human breast carcinoma
(MCF-7) cell line was obtained from the American Type Culture Collection and
was provided by Prof. Marie Ranson from Illawarra Health and Medical Research
Institute, Australia. The cell lines were preserved in the complete culture medium
(detailed in section 3.2.1) and DMSO at -196◦ C (see Figure 3.1).

3.1.2

Biological Reagents

The biological reagents frequently used throughout this research were purchased
from either Invitrogen Life Technologies (Carlsbad, CA, USA) or Sigma Aldrich
(St Louis, MO, USA) unless indicated other-wise. These biological reagents include: GIBCO R Dulbeccos Modified Eagle Medium (DMEM), GIBCO R Foetal
Bovine Serum (FBS), Penicillin Streptomycin (PenStrep), GIBCO R Dulbeccos
Phosphate Buffered Saline (DPBS), GIBCO R Trypsin- ethylenediaminetetraactic
40

CHAPTER 3. MATERIALS AND METHODS

Figure 3.1: The liquid nitrogen tank where cells are stored at -196◦ C at IHMRI,
Wollongong, Australia.
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acid (Trypsin-EDTA), GIBCO R Hanks Balanced Salt Solution (HBSS). GIBCO R
Phosphate-Buffered Saline (PBS). Crystal Violet and Trypan Blue were vital stain
reagents that were implemented in their appropriate staining process. Ethanol (70%
(v/v) in H2O) was employed to dilute the Crystal Violet in the staining process and
as well in a Propidium Iodine staining procedure.

3.1.3

Drugs and Other Chemicals

5-fluorouracil (5-FU), Methotrexate (MTX), 5-bromo-2’-deoxyuridine (BrUdR),
Propidium Iodide (PI), 2’7’-Dichlorofluorescein diacetate (DCFD) and Hoechst
33258 (Hoechst) were purchased from Sigma Aldrich (St Louis, MO, USA). Fluorodex (Fudex) was provided by A/Prof. Ranson from Illawarra Health and Medical
Research Institute, Australia.

3.1.4

Nanoparticles

The tantalum pentoxide nanostructured particles (Ta2 O5 NSPs) was synthesised by
Dr Konstantinov, a member of Institute for Superconducting and Electronic Materials (ISEM). The synthesising process is similar to that described by Huang and
Hsieh [HH10], with fine modification in the tantalum metal was placed inside a furnace at 800◦ C for one hour prior to oxidation process to fabricate nanoparticles.
The nanostructured particles were stored in a double contained with silicon crystals
and placed inside a desiccator to prevent moisture absorption. The nanostructured
particles were sterile at 121◦ C to eliminate introduction of contamination into the
cell culture. Sterilisation involved the use of an autoclave, such as the one shown in
Figure 3.2.

The gold nanoparticles (Au NPs) was an aqueous solution purchased from Meliorum Technologies Inc. (Rochester, NY 14607, USA). The nanoparticles are spherical
shaped with a mean size of 15 nm.
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Figure 3.2: Schematic diagram of a laboratory autoclave sterilisation process [Gup16].

3.1.5

X-rays Irradiator Units

3.1.5.1

Linear Accelerator (LINAC)

The Axesse Elekta LINAC (Elekta AB, Kungstensgatan, Stockholm, Sweden) at the
Prince of Wales Hospital (Randwick, NSW, Australia) in the oncology department
was used for cellular irradiations in the megavoltage (MV) energies range. X-ray
energy of 10 MV was used to irradiate the cells at a dose rate of 5 Gy/min. All
doses (1, 2, 3, 5 and 8 Gy) were delivered in single fractions at room temperature.

3.1.5.2

Kilovoltage (kV) Orthovoltage

The Nucletron Oldelft Therapax DXT 300 Series 3 Orthovoltage unit (Nucletron
B.V., Veenendaal, The Netherlands) at the Prince of Wales Hospital (Randwick,
NSW, Australia) in the oncology department was used for cellular irradiations in
the kilovoltage (kV) energies range. X-ray energies at 125 kV and 150 kV were
used to irradiate the cells at the dose rate of 0.7 Gy per minute and source-to-flask
distance (SFD) of 50 cm. The same range of dose as MV was applied.

A kilovoltage irradiation emits a relatively low energy radiation through bombarding a high Z target (i.e. Tungsten (W)) with high-energy electrons. The additional
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filter was chosen to provide a photon energy spectrum whose effective energy approximates the maximum mass energy absorption for the high Z target relative
to water (as shown in Figures 3.4 and 3.5). This is a means to achieve as close
as possible to maximum dose absorbed in the material as mass energy absorption
coefficients are directly proportional to the absorbed dose in the material. Using
available orthovoltage beam filters at POWH and their associated half value layer
(HVL – see Figure 3.3), attenuation coefficient (µ) was determined via the National
Institute of Standards and Technology (NIST). Subsequently, mass attenuation coefficient (µ/ρ) was determined and the effective energy was found for each filter at
a particular operating voltage (kV).

Figure 3.3: Relationship between effective energy and half- value layer (HVL)
50 for x-ray beams in the superficial and orthovoltage range. Different HVL are
obtained from using different filters; HVL increases with increasing filter thickness
as the beam becomes increasingly harder, that is, contains a greater proportion
of higher-energy photons. Data calculated from the attenuation coefficients of
monoenergetic photon beams.

A specific filter and beam energy was employed to deliver an optimal photon
energy to the high Z target. This optimal energy was chosen to be around the
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optimal photon mass absorption energy of the high Z atom in the material to water,
as this would maximise secondary particle production by the photoelectric effects.
For BrUdR, it is the bromine atom. For Ta2 O5 NSPs, it is the tantalum atom.
The Xmudat program was used to generate photon attenuation coefficients based
on energy absorption for the high Z material and water. The ratio of attenuation
coefficients for the high Z material to water was then graphed as a function of energy
to establish the optimal energy for beam absorption, as shown in Figures 3.4 and 3.5.
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Figure 3.4: Ratio of the total mass energy absorption coefficient of Bromine to
water as a function of energy (corresponding to the y-axis on the left). Output
spectrum of an orthovoltage X-ray unit operating at 125 kVp is also shown (corresponding to the y-axis on the right). The data for the output spectrum was
generated using SpekCalc [Pol+09].

For BrUdR experiments, flasks were irradiated vertically the Pantak unit was
operating at a peak voltage of 125 kVp and 20 mA with additional filtration of
0.1 mm Cu and 2.5 mm Al (HVL = 6.70mm Al). For Ta2 O5 NSPs experiments,
flasks were irradiated horizontally and the unit was chosen to operate at 150 kVp
and 20 mA with additional filtration of 0.35 mm of Cu and 1.5 mm of Al (HVL
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Figure 3.5: Ratio of the total mass energy absorption coefficient of Tantalum
to water as a function of energy (corresponding to the y-axis on the left). Output spectrum of an orthovoltage X-ray unit operating at 150 kVp is also shown
(corresponding to the y-axis on the right). The data for the output spectrum was
generated using SpekCalc [Pol+09].
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= 0.67mm Cu). Beams were calibrated as per international protocols for absolute
dosimetry and relative dosimetry data were applied to correct for changes compared
to reference conditions. More details of the irradiation conditions can be found
in [Okt+15] and [Bro+17].

3.1.6

Sonicator

The Branson Sonifier S-250D digital with Tapered Micro-Tip (Consonic Pty Ltd.,
NSW, Australia) was used for sonication of nanoparticles ( Figure 3.6)

Figure 3.6: A tapered micro-tip ultrasound sonicator.

3.1.7

Overview of Flow Cytometric Process

Flow cytometry (FCM) is a powerful technique for counting and examining microscopic particles, such as cells, by suspending them in a stream of fluid and passing
them by an electronic detection apparatus. The flow cytometer performs this analysis by passing thousands of cells per second through a laser beam at the interrogation
point one cell at a time. As a cell passes through the laser, it will refract or scatter
light at all angles. A number of detectors are aimed at the point where the stream
of cells passes through the laser beam: one for forward scatter (FSC), several for
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side scatter (SSC) and at least one for detecting fluorescent. A fluorescent detector
is required because fluorescent chemicals found in the particle (or attached to the
particle) may be excited into emitting light at a longer wavelength than the laser
beam source. A bandpass filter is placed in the beams so as to prevent any intense
laser light from reaching the detector. A dichroic filter is a very accurate colour
filter and is employed to selectively reflect a colour to the appropriate detector (as
shown in Figure 3.7). Ultimately, this combination of scattered and fluorescent light
is picked up by the detectors and by analysing fluctuations in brightness at each detector (one for each fluorescent emission peak), the flow cytometry software is able
to deduce information on the cellular characteristics.

Figure 3.7: Schematic view of a flow cytometer and sorter with a jet-in-air
configuration showing one forward light scatter, one side scatter and three fluorescence detectors [Lif16].

3.1.8

Microscopes

3.1.8.1

Confocal Microscope

Leica confocal laser scanning microscope (Leica TCS SP5 Advanced System, Mannheim,
Germany) was used to image cells with propidium iodine dye and the nanoparticles
cultured in cells. The microscope is accompanied with image manager software Leica Application Suite Advanced Fluorescence (LAS AF, v.2.6.17314, Germany) at
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IHMRI, Wollongong, Australia (Figure 3.8).

Figure 3.8: Leica confocal laser scanning microscope (Leica TCS SP5 Advanced
System - X1-Port Access with SMD FCS and CO2 incubation chamber, Germany)
at IHMRI.

3.1.8.2

Fluorescence Microscope

Leica DMI8 fluorescent microscope (Leica TCS SP8 Advanced System, Mannheim,
Germany) was used to image cells with Hoechst stain and DCFD dye with and
without the nanoparticles cultured in cells. The microscope is accompanied with
image manager software Leica Application Suite X (LAS X, v.2.6.17314, Germany)
at IHMRI, Wollongong, Australia (Figure 3.9).

3.1.9

IncuCyte

IncuCyte R ZOOM system (Essen BioScience, Meadowbrook, Australia) allowed
observation and quantification of cell behaviour over time. The IncuCyte system
is accompanied with analysis system software at IHMRI, Wollongong, Australia
(Figure 3.10).
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Figure 3.9: Leica DMI8 fluorescent microscope (Leica TCS SP8 Advanced System - UV-VIS-IR and X1-Port Access with SMD FCS and CO2 incubation chamber, Germany) at IHMRI.
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Figure 3.10: IncuCyte R ZOOM system (Essen BioScience, Meadowbrook, Australia) at IHMRI, Wollongong, Australia.
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mEHT

mEHT applied via the LAB-EHY 100 laboratory unit associated with the in vitro
applicator (Oncotherm GmbH, Germany). The unit features a wide-range loads with
quartz, special quvettes and thermocouple probe. The unit offers a precise output
power and treatment time control, but in accordance to the device specifications.

3.1.11

Waterbath

The hyperthermia clinical device is not accessible for this preclinical study. For
this reason, waterbath is used to study hyperthermia treatments as a control for
the mEHT experiments in vitro. The waterbath is a laboratory equipment made
from a container filled with heated water. It has an accurate digital solid state
temperature controller, which allow users to set a desired temperature. The calibration of waterbath temperature was verified in this study using a calibrated mercury
thermometer.

Figure 3.11: The waterbath at IHMRI, Wollongong, Australia.
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Cell Culture Methods
Thawing Cells in Cryopreservation

Cells were contained in the cryogenic vial in DMSO and preserved in the liquid
nitrogen. Cells needed to be thawed to ‘resuscitate’ them and prepare for usage in
experiments. The cryogenic vial from the liquid nitrogen was placed in a 50 mL tube
containing pre-warmed 70% ethanol. The tube was held in the 37◦ C waterbath until
the cells are thawed. The cells were transferred into a T75 cm2 BD FalconTM Tissue
Culture Flasks. Pre-warmed complete culture medium made from DMEM with
10% FBS and 1% PenStrep was added to the cells in dropwise. This was done to
slowly introduce the cells into a new culture environment. Once the entire cultured
medium was added, the cells were gently pipette up and down. A small aliquot
was taken and counted to check the viability of the cells using Trypan blue stain,
a haemocytometer, and a microscope, a procedure described in section 3.2.3. The
remainder cells in the flask were maintained in a 37◦ C humidified 5% (v/v) CO2 cell
culture incubator (Heracell 150i). Once the cells were settled and attached to the
flask, new culture medium was replaced. When the cells reached 85% confluence
in the flask, they were washed twice with DPBS without magnesium and calcium.
The adherent cells were detached from the surface of the flask by adding 1-2 ml of
Trysin-EDTA, ensuring that all cells are covered. The flask was incubated for 2-4
minutes to allow for the cells to detached, after which the sides of the flasks were
gently tapped to assist with this process. The cell suspension was centrifuged to
remove the DMSO from the cells. The cell pellet were resuspended in the culture
media and maintain and subculture as detailed in the section 3.2.2.

3.2.2

Passaging Cells

Cells were grown and passage using T75 cm2 BD FalconTM Tissue Culture Flasks.
The cell culture media was made from DMEM with 10% FBS and 1% PenStrep, to
promote cell growth. At 80% confluence, the culture medium was carefully removed
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from the flask and the monolayers of cell were washed twice with DPBS without
magnesium and calcium. The adherent cells were detached from the surface of the
flask by adding 1-2 ml of Trypsin-EDTA to the flasks, ensuring that all cells are
covered. The flask was incubated for 2-4 minutes to allow for the cells to detach,
after which the sides of the flasks were gently tapped to assist with this process. The
flask was placed under the microscope to confirm that all the cells were detached.
The cells were resuspended by adding 10ml of fresh pre-warmed medium using a
sterile pipet tip and pipettor. The content was pipetted up and down, which in
turn quenched the Trypsin-EDTA. A small aliquot of cell suspension was taken
and counted to check the viability of the cells. The cells were then seeded into
a fresh T75 cm2 tissue culture flask to achieve a desire cell seeding density (for
example, 5 × 105 cells/ml for 9L cells). A new 25ml of DMEM was subsequently
added to enhance cell growth. The flask was incubated until next passaging of cells.
Throughout the experiments, the passage number used was in between 10 to 25.
Too high of a passage number is avoided in experiments, because these “working
cultures” if passaged enough times can show evidence of genetic drift. That is,
changes in genotype from the original reference strain which may or may not result
in observation changes in phenotype. Hence, when this situation occurred, the cells
are discarded and fresh cells are thaw out, process described in section 3.2.1. The
new thawed out cells are then incorporated to begin a new original reference strain.

3.2.3

Cell Counting Procedure

Cell counting procedure is utilised for finding cells concentration on most occasion.
By counting the cells in a known volume of culture, the concentration (for example, 5 × 105 cells/ml for 9L cells) can be mediated. Known cell concentration is
critical for two reasons; the adjustment of drug applied in the experiment according
to the concentration of the cells and the measurement of cell viability. The latter
would allow for measurement and calculation of the fraction of surviving cells after
being exposed to drug, nanoparticles and radiation. Cell counting was performed
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using haemocytometer and cover-glass which needed to be adhered via suction to
the haemocytometer where “Newtons rings” should be able to be seen under the
cover-glass. Prior to cell counting, the aliquot of cell suspension was sampled after
being subjected to vortex using the Stuart R Scientific SA8 vortex to ensure the
homogeneity in the sample. The sample from the aliquot was diluted in Trypan
Blue (i.e. 1:4 dilution) and 10 µl of this mixture was loaded into each of the two
chambers of the hemocytometer by carefully touching the cover-glass at its edge
with the pipette tip and allowing the chamber to fill by capillary action.

Once completed, the sample was placed under the microscope at 100 times the
magnification with a grid of 9 squares visible in each chamber. Each of the squares
in the chamber has an area of 1 mm2 and the cover-glass resting 0.1 mm above the
floor of the chamber. This resulted in the volume over the central counting area
being 0.1 mm3 or 10−4 ml. An average cell counts were taken from over 10 squares
of both chambers; live cells contained in the outer 4 squares as well as the central
counting square were counted from each chamber (Refer to Figure 3.12 for the layout
of the grid). The number of cells present in the suspension volume is calculated via
the following equation:

No. of cells per ml = (average no. of cells per grid) × (dilution factor) × 104 ,
(3.1)
where 104 represents a conversion factor to get cell numbers per 1 ml.

3.3

Drugs Treatment and Cytotoxicity

Stock solutions of 5-fluorouracil (5-FU), methotrexate (MTX), Fluorodex and 5bromo-2’-deoxyuridine (BrUdR) were prepared in Hank Balanced Salt solution (HBSS)
and stored at -20◦ C. In the cell preparation procedure, 10% cells are seeded in
vented T12.5 cm2 BD FalconTM Tissue Culture Flasks and allow time to grow in
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Figure 3.12: Schematic of Haemocytometer [Sim16].

the incubator. The doubling time of the 9L cells was 36 hours. Deduced from this
demonstration, 100,000 cells seeded per flask would take 5 days to become confluent. The cells required at least one doubling time to attach to the flasks prior to
introducing drugs into the cellular environments. Once the prepared T12.5 cm2
flasks cells have been incubated for the required amount of time (i.e. at least one
doubling time) and the medium was replaced and cells were incubated with 0.01 0.1 µM 5-FU/MTX/Fudex and/or 1-10 µM BrUdR. After 2 doubling times of being
incubated with drugs, the cytoxicity of the drugs was assessed by clonogenic assay
(refer to section 3.7).

3.4

Nanostructured Particles Treatment and Cytotoxicity

Nanoparticle preparation is of importance for the research outline and presented in
this thesis. The characteristics of Ta2 O5 nanostructured particles (NSPs) are depending on their size, structure, and susceptibility to aggregation. In preparing the
NSPs, it is very important to control the particle size, particle shape and morphology.
Scanning Electron Microscopy (SEM) analysis was conducted by Brown [Bro+14]
to ratify the effect of sonication on the aggregation and morphology of tantalum
pentoxide nanoparticles.
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The sample images displayed some large aggregates at approximately 200 microns
when no sonication (see Figure 3.15) was undertaken. Consequently, when the images were taken after the NSPs were sonicated, the result was a global reduction in
the aggregate dimensions (see Figure 3.16).

Specifically, the largest aggregate was observed to be approximately 20 microns,
effectively diminishing the dimensions of the large aggregate by a factor of 10. This
highlights the significance of the sonication procedure in preparing Ta2 O5 NSPs
prior to incorporating them into cells.

Figure 3.13: A SEM image of unsonicated Ta2 O5 NSPs stock solution [Bro+14].

3.4.1

Ta2 O5 Nanostructured Particles Stock Solution

In the biological safety cabinet (BSC), 2 mg of Ta2 O5 NSPs were removed from the
double-contained silicon crystal tube and carefully placed to the bottom of a 15 ml
BD FalconTM tube via utilising a lab digital weight scale. It is a crucial step to
sterilise the NSPs sample prior to introducing it to the cellular environment. This
was achieved by placing the sample tube, with the lid loose to prevent pressure
build-up, in the autoclave on the dry cycle that operates at 121◦ C for approxi-
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Figure 3.14: A SEM image of sonicated Ta2 O5 NSPs stock solution [Bro+14].

mately 50 minutes. Once sterile, Ta2 O5 NSPs was solubilised using a biologically
relevant solution before adding to the cellular environment. This stock solution was
produced by adding 5 ml of PBS (Ca2+ and Mg2+ ) to the fresh sterile 2 mg of Ta2 O5
NSPs, giving a concentration of 0.4 mg/ml. Proceeding from the sonication process
outlined in section 3.4.2, the desired concentration on a given volume is applied
utilising the following equation:

C1 V1 = C2 V2 ,

(3.2)

where C1 is the initial concentration of the solution, V1 is the initial volume of the
solution, C2 is the final concentration of the solution, and V2 is the final volume of
the solution.

3.4.2

Sonication Process

Sonication is a highly system-specific dispersion procedure. It acts by applying ultrasound energy to agitate nanoparticles in an attempt to maximise the homogeneity
of the nanoparticles dispersion in solution.
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The 15 ml BD FalconTM tube containing the nanoparticles was placed and taped
onto a plastic container filled with approximately 3/4 of the way of water so as to prevent extreme local heating cycle during sonication. This simulated a sonication bath
needed for indirect sonication. The fine tip probe of the Branson Sonififier R was
immersed in the sonication bath, where the ultrasound waves must transverse the
bath liquid and then pass through the wall of the sample container before reaching the suspension. This indirect sonication was chosen over immersing sonicator
probe into the suspension to ensure that no change to the suspension volume or the
degradation of nanoparticles would result from an excessive bulk heating. The sonicator bath was placed inside an insulated container filled with ice to further prevent
suspensions from overheating in the process of sonication (see Figure 3.15). The
sample was sonicated in 3 continuous periods of 10 minutes and at 70% amplitude
of ultrasound output immediately prior to adding Ta2 O5 NSPs stock solution into
the cell environment.

Figure 3.15: Experimental setup of the sonication process at an ultra high intensity for 3 continuous periods of 10 minutes. This was done at IHMRI, Wollongong,
Australia
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Exposure of Ta2 O5 Nanostructured Particles in cells

The method of cell preparation in vented T12.5 cm2 BD FalconTM Tissue Culture Flasks is as outline in section 3.3. However, in addition, a freshly prepared
solubilised Ta2 O5 NSPs was added to the cells following a preparation procedure
of Ta2 O5 NSPs outlined in section 3.4.1. After 24 hours of being incubated with
nanoparticles, the toxicity of the NSPs on the cells was assessed by clonogenic assay
(refer to section 3.7).

Seeing that high Z nanoparticles possess great potential for radiosensitisation, the
highest concentration possible of Ta2 O5 NSPs is ideal. The tolerable concentration
level of Ta2 O5 NSPs on 9L cells was investigated and determined by Brown [Bro+14]
to be 50 µg/ml. This became the desired concentration and was therefore applied
in equation (3.2).

3.5
3.5.1

Cellular Irradiation Methods
Chemotherapy Drugs Combination

Confluent cell cultures were grown as a monolayer in 12.5 cm2 cell culture flasks with
a vented screw cap (BD FalconTM ) for all experiments carried out. Immediately
prior to irradiation, the flasks were filled with 30 ml of Hanks balanced salt solution
(HBSS) to give a full scattered irradiated environment, giving the flask total volume
of 35 ml. Flasks with drugs-containing medium have their concentration of drugs
adjusted for this new volume in the flasks. Non irradiated control samples were kept
at room temperature in the control room while the other samples were irradiated in
the treatment room.

3.5.1.1

Kilovoltage Irradiation

The flasks were positioned vertically upright with cells faced directly at the incident radiation beam. The irradiation field size used for all experiments was 6 × 8
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cm2 at the source-to-surface distance (SSD) of 50 cm. A 10 cm solid water block
(water-equivalent material) was placed behind the flask to accommodate for scattering conditions. Solid water blocks were also placed around the side of the flask to
maintain electronic equilibrium condition within the flask during exposure to radiation. The setup for cellular irradiation experiments involving chemotherapy drugs
is as display in Figure 3.16.

Figure 3.16: The setup for cellular irradiation experiments involving chemotherapy drugs.

3.5.1.2

Megavoltage Irradiation

The orientation of the flasks is as described in previous section (vertical upright
with cells directly facing the incident radiation beam). Solid water blocks (waterequivalent material) were placed both behind and around the sides of the flasks, to
maintain adequate backscattering effects and to stabilise electronic equilibrium. The
flasks were positon at a depth of 2.2 cm in the solid water block to match the dmax
depth of 10 MV photon beam. The irradiation field size used for all experiments
was 10.4 x 10.4 cm2 and the SSD was 100 cm. The setup for cellular irradiation is
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as displayed in Figure 3.16.

3.5.2

Nanoparticle Combination

The monolayer of confluent cell cultures were irradiated in 12.5 cm2 cell culture
flasks with a non-vented screw cap (BD FalconTM ) following 24 hours incubation
with 50 µg/ml of Ta2 O5 NSPs. Non irradiated control samples were kept at room
temperature in the control room while the other samples were irradiated in the
treatment room.

3.5.2.1

Kilovoltage X-ray Irradiation

For kilovoltage X-ray irradiation, a 6 mm depth of medium in the flask was required
to maximise the accuracy of the dose delivered to the monolayer of cells. The flasks
were irradiated in the horizontal orientation to ensure that the nanoparticles are
as close as possible to the monolayer of cell. Solid water blocks were placed both
underneath and around the sides of the flask, to maintain adequate backscattering
conditions and to ensure electronic equilibrium is attained at the depth layer of the
cells (Figure 3.17). The setup for cellular irradiation experiments involving NSPs is
as display in Figure 3.17.

3.5.2.2

Megavoltage Irradiation

Immediately prior to irradiation, the flasks were filled completely with Hanks balanced salt solution (HBSS). This is to avoid air bubbles existing inside the flaks
during the irradiation. The flasks were irradiated horizontally with solid water
blocks placed underneath and around the side of the flask, to maintain adequate
backscattering conditions and to ensure electronic equilibrium is attained at the
depth layer of the cells. The setup for cellular irradiation experiments involving
nanoparticles is as display in Figure 3.17.
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Figure 3.17: The setup for cellular irradiation experiments involving NSPs.

3.6
3.6.1

mEHT
Cell Preparation

Following the procedure in section 3.2.2, cells from the T75 cm2 BD FalconTM Tissue
Culture Flasks were evenly distributed into 2 ml cryogenic tubes. A concentration
of 50 µg/ml of nanoparticles was added into the required cells tubes. For Ta2 O5
NSPs, this 50 µg/ml addition into the tube is following the preparation procedure
outlined in section 3.4.1. These cells tubes were immediately taken for treatment as
outlined in the subsequent section.

3.6.2

Verifying mEHT Thermocouple Probe Reading

Placing the thermocouple inside the cell suspension tube would lead to a contaminated sample and this would have inhibited the study from proceeding further with
experiments. In particular, the clonogenic assay which is ultimately endpoint of the
study. Therefore, the thermocouple probe was placed outside the tube adjacent to
the cell suspension for the mEHT experiments. The approach required was to do
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preliminary tests to gauge what temperature was required for the probe adjacent
to the cell suspension (outside the tube) to reach the desired temperature of 42◦ C
inside the tube.

The cells were in suspension in a small 0.5 ml volume in a small tube (i.e., 2 ml).
The thermocouple probe was placed outside the tube adjacent to the cell suspension. The thermocouple adjacent to the cell suspension was moved along the x- and
y-planes with the z-plane (height) restricted to the volume of the cell suspension,
and temperature readings were recorded for the different measured coordinates. The
average of these readings were taken and applied in the mEHT experiments.

3.6.3

Treatment

Cells suspended in 2 ml cryogenic tubes were immersed in water and exposed for 30
minutes to 42◦ C water temperature either with a conventional waterbath or with the
mEHT unit (see Figure 3.18 for mEHT experimental set up). In addition, mEHT
pre-treated cells and untreated cells were irradiated with 10 MV photon beams from
a Versa HD linear accelerator (Elekta, AB, Kungstensgatam, Stockholm, Sweden)
to a dose of 5 Gy (Figure 3.19). The efficiency of the treatments was assessed using
clonogenic survival assay as described in section 3.7.

3.7

Clonogenic Survival Assay

Clonogenic assays were introduced by Puck and Markus in 1956 [PM56a]. A clonogenic assay is a cell biology technique for studying the effectiveness of specific
agent(s) on the survival and proliferation of cells. It is used in this experiment
to evaluate the effectiveness of the applied treatments on the proliferating tumour
cells as well as healthy normal cells. Procedures involved in this microbiological
technique require precise handling to ensure the possibility of contamination is minimised.
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Figure 3.18: Experimental setup of the mEHT applied via the LAB-EHY 100
laboratory unit associated with the in vitro applicator (Oncotherm GmbH, Germany) at IHMRI, Wollongong, Australia.

Figure 3.19: Radiation setup on the pre-mEHT pre-treated cells at the Prince
of Wale Hospital, Randwick, Australia.
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The clonogenic assay follows the procedure described in section 3.2.2. However,
instead of seeding the treated cells into a new flask, a small volume of cells was
taken for dilution in the DMEM in 50ml FALCON tube. The FALCON tube was
vortexed prior to cell counting with haemocytometer (Refer to section 3.2.3 for
the procedures). Once the transferred process is completed, each flask sample was
seeded into Sigma-Aldrich R 100 mm Petri dishes in either duplicate or triplicate,
as most appropriate with seeding N, 2N, and 3N (N = seeding number). The seeded
Petri dishes were incubated for 15 doubling times [PM56b], after which the fixing
and staining procedures was performed as outlined in section 3.7.1. The storing of
the clonogenic assay Petri dishes in the incubators at 37◦ C temperature with 5%
CO2 concentration is shown in Figure 3.20.

3.7.1

Fixing and Staining

After 15 doubling times of incubation, colonies were formed in the petri dishes. Each
colony is the result of a single cell undergoing multiple divisions during the period
of incubation. The spent medium from each petri dishes were removed and the cell
monolayers were gently washed with approximately 5 ml of DPBS (with Ca++ and
Mg++ ) and discard. The cells were then fixed and stained with approximately 2
ml of mixture solution of 25% crystal violet and 75% ethanol added to each petri
dish. The ethanol serves as a fixation of cell colonies by increasing their rigidity
while crystal violet is used to visualise colonies of cells by staining the colonies
(Figure 3.21). The colonies were washed and the petri dishes were then inverted
drained, leaving the colonies to dry at room temperature overnight (Figure 3.22).
Colonies were counted as surviving if they contained more than 50 cells (observed
by conventional microscope).
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Figure 3.20: Clonogenic assay Petri dishes incubated at 37◦ C temperature with
5% CO2 concentration at IHMRI, Wollongong, Australia.
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Figure 3.21: Crystal violet stain of the cell colonies as a part of the fixing and
staining process.

Figure 3.22: The stained cell colonies after washing the crystal violet stain and
inverted to dry.
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Flow Cytometric Detection
Cell Staining with Propidium Iodine (PI)

A Becton Dickinson fluorescence-activated cell sorting (FACS) flow cytometer is
utilised for the purpose of an analysis of cell cycle of untreated and treated cells.
The cells were harvested following the procedure in section 3.7. However, instead
of seeding them into Petri dishes, we transferred the amount of cells required into
50 ml Falcon tubes. The cells contained within the tubes were washed to remove
serum via adding 5 ml of cold PBS (Ca++ /Mg++ free) and centrifuge (4◦ C) at 1500
rpm for 5 minutes.

The cells were then fixed by first removing the supernatant from the tubes. Follow
on from this is to gently resuspend the cell pellet by adding 1 ml of cold 70% Ethanol,
drop-wise with a Pasteur pipette while vortexing. The reason for the required simultaneous actions was to prevent clustering of cells during the fixation. The cells
were then kept at -20◦ C for at least 60 mins up to a week prior to staining. After
an appropriate time-span, ethanol was removed via centrifuge (4◦ C) at 1500rpm for
5 minutes and the cells were once again washed twice with PBS. The supernatant
was strained out of the tubes prior to staining procedure.

Staining of the cells was then carried out by adding 200 µl PI master mix (100
µg/ml RNase A, 40 µg/mL PI, and PBS pH 7.4) into the tube. After thoroughly
mixing the volume, cells were transported using the PI master mix medium into a
12 × 75 mm, 5 ml high-clarity polypropylene round bottom test tube. The tube
was left to incubate for 60 minutes at 37◦ C. PI is extremely light sensitive and any
exposure of PI from ambient light must be avoided throughout the flow cytometry
procedures. Once the incubated time was completed, the tube was taken out and
the cells inside were analysed by flow cytometry with excitation at 488 nm.
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Cell-Phase Fraction Data Analysis

Cell doublets, dubris and apoptosis were gated out from the two flow cytometric
output dot plot results (see Figure 4.14 as an example) to give a better statistical
result in the histogram plot. The intensity of red fluorescence (i.e. emission fluorescence of PI dye) is displayed in a histogram plot (see Figure 4.15 as an example).
The histogram represents the DNA distribution; the proportion of cells in G0 /G1 ,
S and G2 /M phases of the cell cycle.

3.8.2

Measurement of Internalisation of Nanoparticles

After exposure to NPs for 24 hours, the cells were harvested, centrifuged at 1500
rpm for 5 mins at 4◦ C and washed twice with cold PBS (Ca2+ /Mg2+ free). Flow
cytometric measurements were performed with the forward scatter (FSC) and side
scatter (SSC). A minimum of 10,000 cells were analysed from the harvested cells
sample. Cell doublets and aggregates were gated out from the two flow cytometric output data, as showed in Figure 4.6. The granularity representation in the
histogram was assessed.

3.8.3

Measurement of BrUdR Incorporation in DNA

After the cells are exposed to BrUdR for 2 doubling times, the cells were harvested
and fixed for a minimum of 60 minutes after the addition of 1 mL of cold 70% Ethanol
(as outlined in section 3.8.1). The cells were washed twice with PBS and incubated
with Hydrogen chloride solution at 4 M in dioxane (Sigma) for 20 mins at room
temperature. Successively, the cells were washed with phosphate/acid buffer at pH
7.4 and were washed a second time with antibody dilution buffer (PBS with Triton
X-100 and bovine serum albumin (Sigma)). The cells were then treated with the
clone MoBU-1 antibody and left to incubate for 30 mins at room temperature. After
this, the cells were washed with antibody dilution buffer. The residual pelleted cells
were then counterstained with PI mixture solution (10 µg/ml PI, 100 g/ml RNase
A, and PBS pH 7.4) and further incubated for 30 mins at room temperature. This

CHAPTER 3. MATERIALS AND METHODS

71

compound staining optimised for cellular labelling and detection. The stained nuclei
were measured and analysed using a flow cytometer with excitation at 488 nm.

3.9

Microscopic Analysis

3.9.1

Detecting Internalisation of Nanoparticles in Cells

The cells were grown and cultured with nanoparticles in a
TM

Slide

TM

Lab-Tek

TM

II Chamber

System 4 wells (growth area = 1.8 cm2 ) (Thermos-Scientific). After exposure

to nanoparticles for 24 hours, light and fluorescence microscope images were obtained
using a Leica confocal laser scanning microscope with oil immersion objective lens
and the accompany images manager software Leica Application Suite Advanced
Fluorescence.

3.9.2

Detecting Cell Membrane Integrity with Propidium
Iodine

The propidium iodine staining procedure was carried out in a similar manner as
described for flow cytometry (section 3.8.1). The cells were seeded and grown in
a

TM

Lab-Tek

TM

II Chamber SlideTMSystem 4 wells (growth area = 1.8 cm2 ) after

applying the treatment in the mEHT experiment. The cells were incubated in 37◦ C
until taken for imaging using a Leica confocal laser scanning microscope. Immediately prior to imaging, the cells were washed with PBS (Ca2+ /Mg2+ free), and
200 mL PI master mix was added to the cells. The images were acquired using oil
immersion objective lens and at the excitation of 488 nm.

For imaging immediately after mEHT/waterbath treatment, the cells were centrifuged (23◦ C) and washed twice with PBS. The supernatant was strained out of
the tubes and 200 ml PI master mix was added to the cells pallet. The content was
pipetted up and down, to resuspend the cells. A small volume of the cells mixture
TM

was drop onto a Thermo Scientific

Plain Glass Microscope slide (Invitrogen) and
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a square Thermo ScientificTM Microscope Cover Glass (Invitrogen) was placed on
top of the cells drop. Gentle pressure around the edges of the cover slip was enough
to secure the whole microscope slide unit for the image acquiring process.

3.9.3

Detection of Intracellular Reactive Oxygen Species
(ROS) and Cells Programmed Cell Death

The generation of ROS in 9L cells by Ta2 O5 NSPs was assessed using confocal laser
scanning microscopy. The cells were grown and cultured with NSPs in a
Tek

TM

TM

II Chamber Slide

TM

Lab-

System 4 wells (growth area = 1.8 cm2 ). After exposure to

nanoparticles for 24 hours, the cells were washed with DPBS (Ca2+ /Mg2+ ). The cells
were incubated with 10 µM of Hoechst stain and 10 µM of 2’, 7’-Dichlorofluorescein
diacetate (DCFD) dye for 30 minutes at 37◦ C. The cells were then visualised immediately by the Fluorescence microscope and the accompany images manager software Leica Application Suite Advanced Fluorescence with excitation at 361 nm (for
Hoechst stain – see Figure 3.23) and 496 nm (for DCFD dye). As DCFD is very
light sensitive, the procedure was performed in the dark.

3.9.4

IncuCyte Analysis

IncuCyte R Live Cell Analysis were used to assess the growth rate (proliferation) of
the cells pre-treated with mEHT/waterbath. Subsequent to applied mEHT/waterbath
TM

treatment, a low number of cells were seeded into the Falcon

Polystyrene Mi-

croplates (Invitrogen) and placed in the IncuCyte to commence live cell imaging and
analysis. The results were normalised to the control (untreated cells). This experiment was carried out to investigate if the apoptosis induced by mEHT/waterbath
affects the cell proliferation during the period shortly after the treatment. Each
of the recorded data values are normalised to their corresponding control value to
give a better comparison between the treatment group results. The errors bars are
standard errors of the means (SEM). The experiments were performed three times
independently.
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Figure 3.23: The cells stained with the Hoechst dye allow visualisation of the
cell nucleus. The fragmented nucleus are indicated in the figure.

IncuCyte R Live Cell Analysis were also employed to assist in the assessment of
the selectivity function of mEHT treatmenton on malignant cells. Prior to the
mEHT/waterbath treatment, the malignant (either 9L or MCF-7) and non-malignant
(MDCK) cell lines are transferred into the same tube. The type of tube and the
volume of the cell solution is the same as used in all other experiments previously
described. Similarly, the mEHT/waterbath treatment setup is the same as the other
experiments. After the mEHT/waterbath treatment, the co-cultured non-malignant
cells (MDCK) and malignant cells (either 9L or MCF-7) at the same cell density
as the controls (co-cultured cells without mEHT/waterbath treatment) were seeded
into the wells and imaged every 24 hours over 96 hours. Different cell lines have
different proliferation rates (doubling time) and this was accounted for in the preparation of the co-cultured cells prior to apply the respective treatment for imaging.
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3.10

Clonogenic Assay Data Analysis

3.10.1

Plating Efficiency

After colonies in the petri-dishes were fixed and stained (procedure described in
section 3.7.1). The plating efficiency (P E) was calculated as the number of surviving
colonies (i.e. a colony contained more than 50 cells is regards as surviving colony)
divided by the number of cells seeded:

PE =

3.10.2

Numbers of surviving colonies counted
.
Numbers of cells seeded

(3.3)

Cell Survival Analysis

The number of colonies that arise after irradiation, which is expressed in terms of
P E, is called the surviving fraction (SF ):

SF (D) =

P E(D)
,
P E(0)

(3.4)

Where SF (D) is the survival fraction of the cells at irradiation dose D (Gy), P E(D)
is the plating efficiency of the cells at irradiation dose D (Gy), and P E(0) is the
plating efficiency of the cells exposed to zero irradiation dose (control group). The
cell clonogenic surviving fraction (SF ) was plotted against irradiation dose (D) on
a semi-logarithmic scale. A linear quadratic model (LQ) was fitted to obtained
radiation dose-survival curves. For a single fraction at a dose D (Gy), the SF is
described by the LQ model as
2

SF = e−αD−βD .

(3.5)

The α and β are two the fit parameters (Gy−1 and Gy−2 respectively) determined
by using the OriginLab graphing and analysis software nonlinear curve-fitting algorithm.
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Sensitisation Enhancement Ratio (SER)

The sensitisation enhancement ratio at the 10% survival level (SER10% ) is determined by taking the ratio of doses to achieve 10% cell survival for cells without
treatment (radiation alone) to those with treatment(s) (i.e. 5-FU, BrUdR, Ta2 O5
NSPs or combinations). The errors bars are standard error of the mean (SEM).

Chapter 4
Results and Discussions
4.1

Cloning Efficiency of Plating

The plating efficiency for each cell line is important. It is a standard reference
point as to whether the experiment is a success or reliable. Different cell lines
have different plating efficiency [Fra+06]. The range of the plating efficiency at low
density for 9L and MCF-7 is 6% - 9% and 52%-56%, respectively. The range of the
plating efficiency at low density for MDCK is 31% - 36%. The ranges account for
the variation in the time for the cell to complete one cell cycle. The results are seen
in Figure 4.1.

4.2

Cytotoxicity Test

Cytotoxicity testing provides a crucial means of ranking compounds for consideration in this study. In this chapter, the toxicity of both drugs and nanoparticle on
the 9L cells are presented. The optimum drug concentration and the combination
chosen to take on board in further studies are then detained.
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Figure 4.1: Plating efficiency of 9L, MCF-5 and MDCK cells. Errors bars
represent the SEM.

4.2.1

Drugs Cytotoxicity Incubated at 37◦ C for 48 hours on
9L Cells

Drug

It is important to identify the lowest concentration for a given drug to inhibit the
9L reproductive viability. An identical amount of 9L cells is introduced into petri
dish of media containing specific drug at a specific concentration. A concentration
of 0.01 µM and 0.1 µM were used for 5-FU, Fudex and MTX. Concentration of 1
µM and 10 µM of BrUdR were used. Intuitively, the higher concentration resulted
in higher toxicity on the cells. However, the toxicity effect of this 10 times higher
in concentration is not linear. The additional decrease in the cells survival fractions
from the lower concentration due to higher concentration for 5-FU, Fudex and MTX
is 34%, 10% and 65%, respectively. A 15% decreases from the 1 µM of BrUdR in the
cells survival fraction is also recorded. The relatively high cells survival fractions for
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1 µM and 10 µM of BrUdR is not unexpected. In theory, BrUdR has no cytocidal or
antimetabolite effects on the cells, under no exposure to radiation condition [HS69].
Nevertheless, some chemically toxicity to cells is expected on the fast proliferating
9L cells. This positive toxicity finding of BrUdR agrees with other studies [Kuw+07;
SIM04; CHS05]. In this study, the higher concentration of 10 µM BrUdR is preferred. The idea is to have more Bromide atoms present in the cultured cell when
irradiated with X-ray and preferably to have Bromide in the nucleus/DNA so as to
enhance radiation absorption locally.

In relation to the three antimetabolite drugs, their lower concentration of 0.01 µM
have the potential to combination with another high Z agent (i.e. BrUdR and Ta2 O5
NSPs). Of course, the antimetabolite with the lowest toxicity is desired but this is
not a definite best candidate for the combination. Henceforth, the cell survival fractions are obtained for the combination of each of the antimetabolite at a 0.01 µM
concentration with BrUdR at 10 µM.

Figure 4.2: Normalised survival fractions of 9L cells exposed to different drugs for 48 hours at different concentrations. Errors bars
represent the SEM.
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Drug Combinations

The combination of Fudex and BrUdR resulted in cells survival fraction of 24%.
The synergetic toxicity effect of this combination of drugs is not beneficial for irradiation experiments purposes. It is important that high cell survival fraction is
maintained in the combination to minimise non-irradiated cells toxicity. In the clinical treatment, these cells may be healthy cells that are surrounding the tumour
target. For this reason, the primarily killing effect needs to originate from the X-ray
radiation. In addition, if the combination of chemotherapy agents is too toxic to
the cells, it would as well inhibit the uptake of BrUdR (the high-Z carrier) into the
DNA, and hence diminish the radiation enhancement effects. To satisfy the purpose of the aims of this thesis the toxicity of Fudex (0.01 µM) and BrUdR (10 µM)
combination, and MTX (0.01 µM) and BrUdR (10 µM) combination are both too
high at this concentration. This drug combinations results (Figure 4.2) underlined
the best combination for further studied to be 5-FU (0.01 µM) and BrUdR (10 µM)
with the highest survival fraction of 65%.

4.2.2

Validation of mEHT Thermocoupled Probe Temperature Reading

The average temperature readings of the thermocouple adjacent to the cell suspension was found to be (41.2 ± 0.3)◦ C. Finally, at a fixed coordinate outside the
tube, we set the temperature to 41.2◦ C to reach the desired average value inside
the tube of 42◦ C. Although this means of obtaining the target temperature seems
somewhat ad hoc, it should be emphasized that the cell suspension volume is quite
small (i.e., 0.5 ml) and thus, temperature equilibrium would be reached very quickly.
It should also be noted that the difference in temperatures in the experimental setup between the outside and inside environments of the cell suspension tube was
very small, and this was difference was determined to be a discrepancy of 0.8◦ C.
The fixed coordinated used and the temperature reading found subsequently both

CHAPTER 4. RESULTS AND DISCUSSIONS

81

became benchmark parameters for the mEHT experiments that followed.

4.2.3

Tantalum Pentoxide Nanostructured Particles Cytotoxicity

In this study, the cells are exposed to 50 µg/ml tantalum pentoxide nanoparticles
(Ta2 O5 NSPs) under two different conditions in their respective experiments. This
is described in the following subsections.

4.2.3.1

Incubated at 37◦ C for 24 hours on 9L cells

The Ta2 O5 NSPs displayed modest toxicity on 9L cells. The cells survival fraction
after 24 hours exposure to 50 µg/ml of Ta2 O5 NSPs was determined to be 82 ± 3%.
When coexistent with 0.01 µM of drug, it scarcely increased the toxicity of its drug
component, within their uncertainties. The cytotoxicity of the individual combination of MTX and 5-FU with Ta2 O5 NSPs resulted in the cells survival fractions of
73 ± 4% and 71 ± 5%, respectively. The combination of 5-FU with Ta2 O5 NSPs
was chosen to be the one used for the one used for the central investigation so as to
keep this study synchronised with the drug combinations of 5-FU and BrUdR.

4.2.3.2

Incubated at room temperature for 4 hours on 9L, MDCK and
MCF-7

The condition of incubating the Ta2 O5 NSPs with the cells at room temperature
for 4 hours is a consequent of the imposed restriction in the mEHT set-up. The
cytotoxicity of the Ta2 O5 NSPs was performed on 9L, MCF-7 and MDCK cells line
and the results are displayed in Figure 4.4. The results showed Ta2 O5 NSPs posed
no toxicity effect on the 9L cells. On the other hand, the MCF-7 cells survival
fraction decreases to 62 ± 9%. The MDCK cells survival fraction is 85 ± 5%.
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Figure 4.3: Normalised survival fractions of 9L cells following 3-days exposure
to 0.01 µM of drug. On the 3rd day, this was followed by 24-hours exposures to
the Ta2 O5 NSPs. Cells were incubated with the drug and nanoparticle at 37◦ C.
Errors bars represent the SEM.
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Figure 4.4: Normalised survival fractions of 9L, MCF-7, and MDCK cell lines
exposed to Ta2 O5 NSPs for 4 hours and incubated at room temperature. Errors
bars represent the SEM.

4.2.4

Gold nanoparticles cytotoxicity

Bulk gold is well known to be biocompatible and chemically inert [Fin+76]. Sizes
that are larger than 5 nm is generally considered as having the chemically inert
property resembling its bulk size. In this study, an average size of the gold nanoparticles (Au NPs) is 15 nm. To align the same concentration as used for Ta2 O5 NSPs
for mEHT experiments, 50 µg/ml of Au NPs is applied to the cells.

4.2.4.1

Incubated at room temperature for 4 hours on 9L, MDCK and
MCF-7

The cytoxicity results of Au NPs on 9L, MCF-7 and MDCK cell lines are shown
in Figure 4.5. High cell survival fractions is observed for MCF-7 and MDCK cell
lines, bestowed 96 ± 7% and 98 ± 4%, respectively. The toxicity of Au NPs on 9L
cells obtained a survival fraction of 73 ± 5%. The low toxicity effect of Au NPs on
the cell lines was unsurprising because of its biocompatible material. However, the
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magnitude of its toxicity on the 3 cell lines was not of significant concern in this
study.

Figure 4.5: Normalised survival fractions of 9L, MCF-7, and MDCK cell lines
exposed to Au NPs for 4 hours and incubated at room temperature. Errors bars
represent the SEM.

4.2.5

Conclusion

Cytotoxicity effect of the drugs, allow for the most favourable concentration of 0.01
µM for 5-FU, MTX and Fudex to be taken and used for other experiments. The
most favourable drug combinations was 5-FU (0.01 µM) and BrUdR (10 µM) because of its highest 9L cells survival fraction compared to other combinations of
drugs (i.e. MTX+BrUdR and Fudex+BrUdR). This is important not only from
the therapeutic point of view but also for the clonogenic assays in the subsequent
radiation experiments where the cell survival viability needs to be assessed.

Ta2 O5 NSPs showed excellent biocompatibility. Its toxicity effect when combined
with 5-FU (0.01 µM) remained low. This encouraged the next step in the study,
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which was the investigation of the potential enhancement of the biological effect of
the X-ray irradiation by invoking this treatment combination on the 9L cells.

The toxicity effect of Ta2 O5 NSPs and Au NPs under the 4 hours at room temperature incubation with 9L, MCF-7 and MDCK cells lines were investigated purely for
the mEHT investigation experiments. The important of their toxicity effect results
mainly served as a reference point as the main focus was on the validation of the
mEHT treatment.

4.3

Utilisation of Tantalum Pentoxide Nanoparticles

4.3.1

Internalisation in 9L cells

Flow Cytometry
The changed in side scattering (SSC) mean and forward scattering (FSC) mean
represents the relative change in granularity and size of the cell, respectively. The
gating is restricted between 60% - 100%, to allow analysis only of cells the size of
lymphocytes. From this the amount of internalisation of Ta2 O5 NSPs on the cells
is measured to increase the cellular granularity by 45%. This measurement is used
as a marker for internalisation of NPs.
Confocal Microscope

Figure 4.7 b) show a relatively even distribution of 50 µg/ml of Ta2 O5 NSPs across
the cell culture after 24 hours exposure to NSPs. The aggregation of the nanoparticles is observed at a size that is on the micrometer scale. This indicated the limitation of our NSPs to homogenously be distributed across the monolayer cultured
cells. Nonetheless, the figure showed that the NSPs are positioned in the culture in
three possible manners; inside the cells, on the cells and in close proximity to the
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Figure 4.6: Flow cytometric measurements of the amount of internalisation of
Ta2 O5 NSPs in cells (a) control sample set of cells that was incubated without
NSPs (b) cells that incubated with NSPs 24 hours prior to measurement.

cells.

4.3.2

Apoptosis and Reactive Oxygen Species

Apoptosis was detected by nuclear fragmentation using Hoechst nuclear staining.
The percentage of cells showing apoptotic features results are shown in Figure 4.9
a). The percentage of nuclear fragmentation detected for the 9L cells was 19.7 ±
3.4%. Cells that were treated with 50 µg/ml of Ta2 O5 NSPs for 24 hours have 54.5
± 2.5% of nuclear fragmentation detected. The percentage of nuclear fragmentation
observed to increase sharply after exposure to Ta2 O5 NSPs after 24 hours.
A region of interest was selected for both control and Ta2 O5 NSPs as shown
on Figure 4.8 and was represented by ROI.01 on the images. The increase in ROS
induced by Ta2 O5 NSPs was calculated from the mean DCF fluorescence intensity
to be just 1.9%. It is apparent that there was an increase in ROS intensity from Figures 4.8 and 4.9 b) for Ta2 O5 NSPs treated cells, conversely so does the background
fluorescence intensity with a minimum value of 798 recorded. This broadening of fluorescence intensity range resulted in the invariable DCF fluorescence intensity value.
Thereupon, indicated that the Ta2 O5 NSPs does not induced ROS in intracellular.

Figure 4.7: Confocal microscope images of (a) 9L cells that were incubated without NSPs (b) 9L cells that incubated with NSPs 24 hours
prior to imaging. Scale bar: 100 µm.
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Figure 4.8: Fluorescence microscope images of 9L cells probed with Hoechst and DCFD dyes. Cells were treated with 50 µg/ml Ta2 O5
NSPs for 24 hours prior to exposing to the dye. Treated and untreated cells with Ta2 O5 NSPs were analysed for fluorescence with an
excitation of a 352 nm for Hoechst and 495 nm for ROS. An additional overlay images corresponding to the fluorescence of Hoechst and
ROS fluorescence image with and without intracellular. Scale bar: 50 µm.
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(a)

(b)

Figure 4.9: Quantitative analysis of the microscope images of 9L cells incubated
with and without NSPs of (a) nuclear fragmentation using Hoechst nuclear staining and (b) ROS fluorescence intensities expressed as the DCF fluorescence intensity and number of events (Counts) from the selected region of interest (ROI.01)
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Discussion

The potential detrimental health effects of nanomaterials has been of great concern
since the naturally occurring microscopic fibres known as asbestos [Fed11]. In vitro
models are therefore considered to be more favourable for assessing and evaluating
the ability of nanomaterials to elicit disease and their potential toxicity. The amount
of internalisation of Ta2 O5 NSPs into cells is limited by not only their large size (10100 nm in diameter) but also their aggregation size of 10-100 µm. This was observed
in the confocal and fluorescence images. The sonication method was optimised in
a best possible way allowed but aggregation could not be avoided. This occurring
of aggregation was found to be a consequent of how the nanoparticles were synthesized. Other researchers in the team have undertaken a new synthesising method of
Ta2 O5 NSPs to reduce the NSP size, but this work is outside the scope of this thesis.

Cells in their natural environment produce ROS. ROS play a vital role in cellular
signalling, including apoptosis. A significant increase in ROS beyond their natural
production can lead to the development of fibrosis and many cancers. This increase
in ROS can be due to the presence of a nanomaterial and the effect can be significant
with the large surface area in some nanoparticles [Puj+11]. Beneficially, the Ta2 O5
NSPs used in this study do not induced ROS in the intracellular medium. This
is notwithstanding the large Ta2 O5 NSPs size due to aggregation observed in the
confocal images and in the fluorescence bright field image in Figure 4.8. The DCF
fluorescence intensity results leads to a consideration that the sudden increase in
apoptosis detected was not induced by the ROS generation from the Ta2 O5 NSPs.
This increase in the number of apoptosis cells detected was believed to be the early
stages of p53-induced apoptosis which is reversible [Ges+01]. This consideration
was based on the clonogenic assay results with a cells survival fraction as high as 82
± 3% was obtained.
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Conclusion

The insignificant internalisation of Ta2 O5 NSPs in the intracellular medium does
shed light on the results related to the MV radiation dose enhancement – owing
to the large nanoparticles size and their aggregation. Ta2 O5 NSPs have negligible
cytotoxicity and the apoptosis detected in cells after 24 hours exposure to the NSPs
was believed to be short-term. In addition, Ta2 O5 NSPs does not induce ROS
generation which makes it a suitable candidate for use in treatment of tumours that
are surrounded by critical organs at risk. An example of these tumours is brain
cancers where radiation dose could be locally increased without cytotoxicity effects
to surrounding healthy cells.

4.4

Radiosensitisation Enhancement Effect of Ta2O5
NSPs in Combination with 5-Fluorouracil Antimetabolite

4.4.1

Results

4.4.1.1

Radiosensitisation of 5-FU + Ta2 O5 NSPs on 9L cells with 150
kVp X-rays beam

Cells pre-exposed to 0.01 µM 5-FU for 48 hours and 50 µg/ml Ta2 O5 NSPs for
24 hours were irradiated at the POW hospital in a 150 kVp irradiation field and
the resultant survival curves are presented in Figure 4.10. The survival curve of
Ta2 O5 NSPs displayed no radiosensitising enhancement relative to the control curve.
Particularly worth noting, is that the Ta2 O5 NSPs were irradiated in the optimum
energy spectrum, however the results indicate that this form of the NSP seems to
be ineffective in increasing radiosensitisation in the 150 kVp radiation environment.
Cells treated with 5-FU alone displayed radiation resistivity. This was reflected in
the decrease in α and significant increase in the β components of the linear quadratic
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curves compared to the control (results are displayed in Table 4.1). Nevertheless,
the combination of 5-FU and Ta2 O5 NSPs exhibited a radiation enhancement effect
which can be seen from Figure 4.10 and the correspondingly deduced α value (±
SEM), with the components of the linear quadratic curves is evident on Table 4.1.
The combination attained a deduced α of 0.35 ± 0.01 Gy−1 which is higher than
the control (0.27 ± 0.04 Gy−1 ).

Table 4.1: Radiation sensitivity parameters for 150 kVp irradiated gliosarcoma
cancer call line treated with 5-FU and Ta2 O5 NSPs with and without the individual components of the combination.

4.4.1.2

Radiosensitisation of 5-FU + Ta2 O5 NSPs on 9L cells with 10
MV X-rays beam

In view of the clinical importance of MV radiation therapy, the 5-FU + Ta2 O5
NPs combinations were also assessed using 10MV. Similar to what observed in kilovoltage radiation, 5-FU demonstrated no effect in sensitising cells as shown in the
Figure 4.11. Ta2 O5 NSPs showed to have a radiation enhancement effect on cells
at this higher irradiation energy. This is reflected in the α value (± SEM) for the
irradiated cells with Ta2 O5 NSPs (0.32 ± 0.01 Gy−1 ) being higher than the control
(0.19 ± 0.01 Gy−1 ) as displayed in Table 4.2. A greater radiation enhancement effect
was observed in the combination of 5-FU and Ta2 O5 NSPs, but not to a significant
extent. The α value (± SEM) for the treatment combination is 0.37 ± 0.02 Gy−1
and the value appears to be achieved from linear combination of the two individual
treatments. However on closer inspection, the irradiated cells with treatment com-

Figure 4.10: Dose effect relationship of 9L cells irradiated with orthovoltage x-rays and pretreated with 0.01 µM 5-FU + 50 µg/ml
Ta2 O5 NSPs with 150 kVp X-ray with and without individual components of the combination, of 3 independent experiments. Errors bars
represent the SEM.
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bination sees absolutely no shoulder in its survival curve, displaying no β value in
Table 4.2. This indicated that the damage on the target was more lethal.

Table 4.2: Radiation sensitivity parameters for 10 MV irradiated gliosarcoma
cancer cell line treated with 5-FU + Ta2 O5 NSPs with and without the individual
components of the combination.

4.5

Radiosensitisation enhancement effect of BrUdR
in combination with 5-Fluorouracil antimetabolite

4.5.1

Brief History of 5-FU + BrUdR Application

The simultaneous addition of the 5-FU drug and the BrUdR in radiation treatment
had been shown to significantly enhance the uptake of BrUdR into the cell nuclei in
vitro [HS69]. Moreover, they also found the combination of the 5-FU drug and the
BrUdR has resulted in an increase in the irradiation sensitisation effects [HS69]. A
possible explanation for their findings, according to [HS69], was that the presence of
5-FU in the DNA inhibits the biosynthetic mechanism, therefore forcing the cells in
the mitotic stage to uptake thymidine analogue, BrUdR, in order to supply sufficient
thymidine required to duplicate the DNA cells. This explanation is based on their
assumption that the cells do not voluntarily incorporate BrUdR during their mitosis

Figure 4.11: Dose effect relationship of 9L cells irradiated with 10 MV x-rays and pretreated with 0.01 µM 5-FU + 50 µg/ml Ta2 O5
NSPs with and without individual components of the combination, of 3 independent experiments. Errors bars represent the SEM.
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because they can synthesise the thymidine required for this DNA duplication. Due
to this area of research being currently unexplored, more studies are required to
elucidate the relationship between the 5-FU drug and the BrUdR compound in
radiation treatment, as well as the impact on treating cancerous cells.

4.5.2

Results

4.5.2.1

Radiosensitisation of 5-FU + BrUdR on 9L cells with X-rays
energy of 125 kVp

The survival fraction of 9L cells following irradiation with 125 kVp alone and with
drug(s) treatments is shown in Figure 4.12. 5-FU demonstrated no enhanced sensitisation effect of the x-ray irradiation on the clonogenic survival of 9L cells. The
alpha value (± SEM) for 5-FU treated cells (0.19 ± 0.01 Gy−1 ) was the same as the
control (0.21 ± 0.03 Gy−1 ), within their uncertainties. This was expected because
of the similar results obtained for cells treated with 5-FU in the 150 kVp irradiated
energy. The survival curve of cells treated with BrUdR significantly enhanced the
biological effect of the X-ray irradiation by reducing the clonogenic survival of 9L
cells (see Figure 4.12). This was supported by the increase α value from the control
as displayed in Table 4.3. Finally, the survival curve were substantially decreased
with the cells treated with the combination of 5-FU and BrUdR compared to the
sensitise effect of their individual components (Figure 4.12). This is reflected in
α value (± SEM) with the 5-FU + BrUdR (0.47 ± 0.03 Gy−1 ) being significantly
higher than the control (0.21 ± 0.03 Gy−1 ) and the BrUdR (0.29 ± 0.04 Gy−1 ).
This significant degree of radiation dose enhancement bestowed a synergistic effect
as a result.

4.5.2.2

Radiosensitisation of 5-FU + BrUdR on 9L Cells with X-rays
energy of 10 MV

The survival fraction of 9L cells following irradiation with 10 MV alone and with
drug(s) treatments is shown in Figure 4.13. The reduced clonogenic survival curve of

Figure 4.12: Dose effect relationship of 9L cells irradiated with orthovoltage x-rays and pretreated with 0.01 µM 5-FU + 10 µM BrUdR
with 125 kVp X-ray with and without individual components of the combination, of 3 independent experiments. Errors bars represent the
SEM.
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Table 4.3: Radiation sensitivity parameters for 125 kVp irradiated gliosarcoma
cancer cell line treated with 5-FU + BrUdR with and without the individual
components of the combination.

BrUdR illustrated the enhanced biological effect of the X-ray irradiation. This was
reflected in the increase α value (± SEM) with BrUdR attaining 0.39 ± 0.03 Gy−1
compared to the control (cells irradiated alone) α value of 0.19 ± 0.01 Gy−1 . In addition, the quadratic β parameter with BrUdR (0.006 ± 0.001 Gy-2) was lowered than
the control (0.010 ± 0.002 Gy−2 ) which indicated an increase in therapeutic ratio
(α/β ratio). This result is inconsistent with the work of Franken et al. [Fra+13] and
Oktaria [Okt+15] who reported that halogenated pyrimidines, including BrUdR, is
not expected to influence the quadratic β parameter.

The results for the 9L cells treated with combined 5-FU and BrUdR administered
concomitantly with 10 MV irradiation showed a cell kill greater than what achieved
by its individual components alone. The significant increase of the α value to 0.43
± 0.02 Gy−1 was obtained and the quadratic parameter β decreased to none. This
indicated an increase in therapeutic ratio (α/β ratio) which is significant from the
clinical view point.

4.5.2.3

Cell Cycle Analysis with 125 kVp X-rays Energy and Quantification of BrUdR Incorporation into DNA Simultaneously

BrUdR is a halogenated pyrimidine that has a similar chemical structure with the
natural pyrimidines and thus can be mistakenly incorporated into the newly formed

Figure 4.13: Dose effect relationship of 9L cells irradiated with 10 MV x-rays and pretreated with 0.01 µM 5-FU + 10 µM BrUdR with
and without the individual components of the combination, of 3 independent experiments. Errors bars represent the SEM.
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Table 4.4: Radiation sensitivity parameters for 10 MV irradiated gliosarcoma
cancer cell line treated with 5-FU + BrUdR with and without the individual
components of the combination.

DNA chains during the DNA synthesising phase. BrUdR is therefore a provider of
high Z-radiosensitiser atoms (i.e. bromine) which are incorporated into DNA. The
flow cytometer measurements 32% of the total substitution of BrUdR for thymidine
into nucleus DNA was achieved (see the second image of Figure 4.14). However,
the presence of 5-FU that served to inhibit thymidine synthesis did not increase the
uptake of the BrUdR into cells DNA (see the third image of Figure 4.14).

The presence of 5-FU did result in the radiosensitising enhancement of BrUdR,
being the greatest at 125 kVp X-ray energy (see Figure 4.12). Nonetheless, this
effect was not observed in the DNA measurement with propidium iodine (PI) to
determine whether the drugs and / or radiation combination will alter the cell cycle progression (see Figure 4.15). The proportion of the cells in each of the phases
remain unchanged for all applied treatments. This leads one to believe that the
cytotoxic effect of 5-FU on 9L cells was not immediate. In addition, the concentration of 5-FU applied on the cells was 100 times lower than IC50, which was not
sufficient to have an influence on the cell cycle. The effect of 5-FU on the cell cycle
progression extended to its combinations with the “non-toxic” halogenated pyrimidine analogue, BrUdR. The hypothesis here is that the radiosensitising enhancement
effect observed in the survival curve was dominated by the effect of 5-FU. The effect
of the 5-FU in inhibiting cells to repair was gradual. For this reason, its effect was
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not observed directly in the DNA measurement that was acquired immediately after
exposure to radiation.

4.6

Radiosensitisation Enhancement Effectiveness
Comparison of 5-FU+ BrUdR and 5-Fu +Ta2O5
NSPs

4.6.1

Introduction

There is a rapidly growing evidence to suggest an effectiveness of both BrUdR with
5-FU and Ta2 O5 NSPs with 5-FU in cancer treatment research [HS69; Li+10]. However, to date, there has been no study in the field that compared the effectiveness
between BrUdR and Ta2 O5 NSPs in treating the cancerous cells, when simultaneously combined with 5-FU anti-cancer drug. The finding of this study can potentially
provide a guide to the future direction of this cancer research. Moreover, it may
eventually lead to a significant improvement of the treatment outcome as well as
the therapeutic effectiveness.

4.6.2

Comparison of the radiation sensitisation effects of
both BrUdR compound and Ta2 O5 NSPs in kV and
MV

The interaction of BrUdR with x-rays results in the emission of Auger electrons, photoelectrons, Compton scattering electrons, and electron-positron pairs. The range
of these charged particles varies from the nanometer-scale to several micrometers.
Whilst the interaction of BrUdR-treated cells with x-ray has a higher interaction
cross section at lower radiation energy (kV), using higher energy (10 MV) photons
has demonstrated to be just as effective. Evidence for this was illustrated in Figure 4.16 which reflects the SER10% values of 1.58 and 1.53 respectively. The result
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Figure 4.14: Flow cytometric measurements of the amount of Bromide from
a 10 µM concentration that is accessible to the DNA and is displayed in the
graphs of the total DNA content (red fluorescence-575/26-A) versus amount of
incorporated BrUdR (green fluorescence-515/20-A) (a) control sample that was
incubated without 10 µM BrUdR and 0.01 µM 5-FU (b) cells incubated with 0.01
uM 5-FU for 2 doubling time (c) cells that incubated with 10µM of BrUdR for 2
doubling times (d) cells incubated with 10 µM BrUdR and 0.01 µM 5-FU for 2
doubling times, before added fluorescently labelled anti-BrUdR antibodies prior
to measurement. The assay was performed twice.
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Figure 4.15: Flow cytometric measurements of a single parametric DNA diagram of 9L cells stained with PI after exposure to 2 doubling time of (a) without
drugs/irradiation (b) with 0.01 µM 5-FU (c) with 0.01 µM 5-FU and 10 µM
BrUdR (d) and 0.01 µM 5-FU and 10 µM BrUdR combine with 8 Gy X-rays
radiation of 125 kVp. The assay was performed at least 6 times, a representative
example is shown.
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obtained in this experiment for the radiosensitisation effect of BrUdR using the kV
energies is incongruent with that of Aoyama et al. [Aoy+64].

An increase in the α component and the α/β ratio in the LQM suggests a greater
early response for the BrUdR exposed 9L cells to the MV irradiation, when fit to
the SF data at 10 MV compared to 125 kVp. The increase in therapeutic ratio (α/β
ratio) was also contributed by the decrease in the quadratic β parameter. This result is inconsistent with the work of Franken et al. [Fra+13] and Oktaria [Okt+15]
who reported that BrUdR is not expected to influence the quadratic β parameter.
Thus, this positive result for BrUdR in the MV irradiated energies could highlight
future clinical potential of BrUdR.

The increase in therapeutic ratio (α/β ratio) achieved for BrUdR in the 10MV
is most likely due to the interaction between the BrUdR compound surrounding
the cell nucleus and the Compton scattering electron. Compton scattering electron
is the dominant interactive mechanism for MV photons in water. This interaction
resulted in significant number of secondary electrons being formed within a cell.
Additionally, the back scattered photons (approximately 120 keV median energy)
was also found to interact with the BrUdR compound, contributing to a greater
number of secondary electrons being created. Together, forming of these secondary
electrons meant a more densely ionisation tracks at the DNA site. This aids the cells
in becoming more responsive and susceptible to radiation, which in turn enhanced
the effectiveness of the treatment.

The radiation enhancement effect of BrUdR has been shown to be independent
of the photon energy as opposed to Ta2 O5 NSPs that displayed a radio-enhancing
effect only in the MV energy beam (i.e. SER10% of 1.29). The radio enhancing
effect of Ta2 O5 NSPs found in this study was comparable to a previous research
that reported a SER10% of 1.33 for the thermal decomposition synthesising Ta2 O5

CHAPTER 4. RESULTS AND DISCUSSIONS

105

NSPs material [Bro+14; Bro+17; McK+16].

High-Z NPs in close proximity to the beam increases the low-energy component of
the high energy spectra of the beam by releasing lower energy photons via Compton
scattering interactions [Ret+15] and pair production. Consequently, these photons
then trigger the photoelectric or Compton effects that resulted in an increase RBE
to the surrounding tissue. In the case of an in vitro experiment, the surrounding tissue is that of cancerous cells. However, this result did not account for the absence of
the dose enhancement effects of Ta2 O5 NSPs at its optimum radiated energy of 150
kVp (i.e., SER10% of 1.03). Previous research has shown radiosensitisation effects
of the NSPs to be stronger for low-energy beams [Jai+11]. With the Z of Ta2 O5
NSPs as high as 73, a promising dose enhancement is expected for majority of the
high-Z elements present in the cells [Kob+10]. Doubling the Z value of the BrUdR
compound (Z = 35), a high SER10% in kV was also anticipated for Ta2 O5 NSPs
despite the compound being only in close proximity to the cell nucleus. However,
the findings from this study did not demonstrate this.

Nanoparticles radiation dose enhancement is predominantly dependent on a number
of factors such as the size of the nanoparticles, the concentration of nanoparticles
applied, surface properties of nanoparticles and the radiation energy [Xu+09]. As
the surface properties are mainly concerned with the approach of binding to the
cancerous cells in the theranostic system, it is out of our scope in these studies.
The crystallite size of the Ta2 O5 NSPs utilised in this research have a mean size
of 50-100 nm and was irradiated with its optimum 150 kVp X-rays. This was in
keeping with a previous research that reported 50 nm size gold NPs to achieve the
best radiosensitising effect [Chi+10]. However, other studies have reported mixed
findings in relation to the optimal size of NPs [Kon+08; Rah+09; Hai+08]. While a
theory has suggested that sonicating the NSPs prior to adding into the cells should
decrease their size and subsequently increase the internalisation of the NSPs in the
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cells [Bro+14], the result obtained in this research following the internalisation of
Ta2 O5 NSPs in the cells after 24 hours was marginally small. A possible explanation was that the aggregation of the NSPs used in this research has resulted in an
increased NSPs size towards a high end of the expected range (i.e. 100nm value).
Hence, it is plausible that the size of the aggregated Ta2 O5 NSPs may have absorbed the majority of the low-energy short range electrons produced by the kV
radiation. This subsequently hinders the Ta2 O5 NSPs from depositing their energy
on the target cancerous cells. In spite of this finding, the result obtained in this
study is significant by a convention with high Z nanoparticles [Rah+09; Luc+14;
Alg+15], where radiation dose enhancement is dominant in the kV radiated energy.
Firstly, to achieve a dose enhancement in megavoltage for Ta2 O5 NSPs has more
clinical potential than in the kilovoltage region as it could target most of the tumours localisation. Additionally, to also achieve a negligible dose enhancement in
kV irradiation fields for Ta2 O5 NSPs, provide insight for our future in vivo model to
utilise on-board-kilovoltage imaging system (operating range at 40-150 kVp using a
dose approximately 2 cGy) as a part of the image-guided radiotherapy on a linear
accelerator. The absence of dose enhancement in the kilovoltage region would not
increase the energy deposit due to on-board-kilovoltage imager which is an advantage in the sense that this dose enhancement would be very difficult to take into
account precisely as current treatment planning systems do not model kilovoltage
imaging doses accurately.

4.6.3

Influence of 5-FU on the radiosensitising effect of high
Z materials in kV and MV radiation

To date, the combination of 5-FU with radiation has been extensively used and is
the most promising clinical radiosensitiser [ML01]. In this research, the dose enhancement was not observed in the 5-FU survival curve, in all radiated energies.
One possible explanation could be that the concentration of 5-FU used in our studies is 100 times lower than that of IC50. The 5-FU has shown to enhance the

Figure 4.16: Comparison of the sensitisation enhancement ratio (SER10% ) for cells pre-treated with (a) 5-FU+BrUdR and (b) 5-FU+Ta2 O5
NSPs with and without the individual components of the combination in their respective optimum kilovoltage and 10 megavolt photons
energy.
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radiation sensitisation of both BrUdR and Ta2 O5 NSPs in both kV and 10 MV
radiation fields (see Figures 4.13 and 4.11). Particularly, a synergistic effect was
achieved with the 5-FU+BrUdR in the kV. The measured values of SER10% for 5FU+BrUdR and 5-FU+ Ta2 O5 NSPs in the kV energies were significantly different
with an incomparable result of 2.11 and 1.10 respectively (see Figure 4.16). This
significant difference is most likely due to the absence of the radiosensitising Ta2 O5
NSPs at the irradiation environment. Nevertheless, 5-FU did display a visible sensitising effect in combination with both kV and MV irradiation environments. This is
evident by the increase in α component and decrease in β component of the survival
curves (see Tables 4.1, 4.2, 4.3, and 4.4).

At 10MV, the SER10% for both combinations of 5-FU + BrUdR and 5-FU + Ta2 O5
NSPs is measured to be 1.61 and 1.35 respectively (see Figure 4.16). No significant
difference in the degree of enhancement was found between BrUdR and 5-FU +
BrUdR, and Ta2 O5 NSPs and 5-FU + Ta2 O5 NSPs. That is, both combinations
yielded the same percentage increase by 5% in SER10% . In kV energy, the degree of
enhancement observed for the Ta2 O5 NSPs and 5-FU + Ta2 O5 NSPs combination
was nonsignificant (7% in SER10% increased). The degree of enhancement in both
MV and kV is most likely due to the cytotoxicity effect of 5-FU. The reason being
was that no shoulder was observed in the survival curves for both combinations, in
MV and kV (see Figure 4.11 and Figure 4.10). The shoulder denotes the capacity of
cells to repair itself after being damage by radiation, which is a general characteristic
of the cell survival curve after irradiation. In support of this, a study has found the
5-FU drug to independently decrease the width of the survival curve shoulder as the
concentration of the drugs increased in two human cells lines [Kim+93].

The increase in cell radiosensitivity of the 5-FU + BrUdR and 5-FU + Ta2 O5 NSPs
was found to be influenced by the 5-FU drug. In this study, the 5-FU drug alone
was not found to radiosensitise the cell. As such, the increased sub-lethal damage
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achieved in both the 5-FU + BrUdR and the 5FU + Ta2 O5 NSPs combinations was
due to the impact of the Z of BrUdR and Ta2 O5 under irradiation, and the triggering the mechanism of 5-FU to inhibit cell repair. The sensitisation mechanism
of 5-FU was not fully understood in the past however different studies including
Kim et al. [Kim+93] and Nakajima et al. [Nak+79] proposed that 5-FU acted as an
inhibitor of cells repair from radiation damage rather than direct enhancement of
sub-lethal damage during exposure to radiation. The results outlined in this thesis
prove that their hypothesis was indeed correct through a demonstration of the combination of 5-FU with a high-Z compound or NSPs in the 10 MV irradiated energy.

In spite of the aforementioned findings, this study found the sensitisation mechanism of the 5-FU drug is sufficient only in producing a synergistic effect for the
5-FU + BrUdR in the 125 kVp irradiation environment with the cell line tested
(see Figure 4.12). Previous research has shown that for 5-FU to sensitise cells to
radiation, a degree of 5-FU toxicity needs to be achieved [Byf+82]. Translating the
conclusion reached Byfield et al. to this study implies that a higher concentration of
5-FU may be needed in order to observe radiosensitisation at our irradiated energies
and by extension, an accountable SER10% in its combination with the high-Z. Other
research also demonstrated that the 5-FU drug efficiently sensitised another radioresistant cancer cell line with 6 MV x-ray at a concentration of 100 µM [Haj+14]. This
concentration is 10000 times higher at a lower irradiated MV energy than what is
used in this study. Similarly, other research also reported a concentration of 5-FU to
be ≥ 0.1 µM to be the critical combination in radiosensitising a radioresistance colon
cancer cell lines [Oji+06]. Hence, in order to achieve a good synergistic/additive effect between 5-FU and a high-Z compound or NSP in the MV irradiated energies, a
concentration of 5-FU up to at least 100 times higher than what was used in this thesis may need to be trialled. However, such a drug concentration or higher would be
expected to cause a significant increase in cytotoxicity of cells including the healthy
cells. This suggests that the MV energies used in this study is not optimal for the
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in vitro experiments.

4.6.4

Conclusion

The body of work presented in this chapter provides a platform for examining quite
distinctly different, high-Z compounds. The ability of these compounds to exhibit
characteristics in their performance, as a radiosensitiers was of particular interest.
A demonstration of their radiosensitisation potential, in combination with the 5-FU
drug, when exposed to kV and 10 MV irradiation energies, was demonstrated. Despite having a smaller Z than the Ta2 O5 NSPs, the BrUdR achieved a SER10% of
1.5 times higher in the kV photon energy, and 1.2 times higher in the MV photon
energy beam than what was obtained for Ta2 O5 NSPs. This demonstrated the significance of not only targeting the high-Z at the site of the DNA but also maintaining
their distribution within the target volume in order to maximise the radiation dose
enhancement in the clinical relevant irradiated energy of 10 MV. The potential for
combination of the 5-FU with either of the high-Z compounds in radiation treatment
is present but minimal, particularly in the megavoltage radiation environment. In
kV irradiation environments, a synergistic effect is achieved with 5-FU + BrUdR.
At 10 MV, this research showed the 5-FU mechanism of cell kill is by inhibiting the
repair of the damaged cells. The results obtained in the MV study showed the radiosensitisation effect to be minimal, future research could examine ways to enhance
the effect of cell death in the MV energy, given that high-energy beams are currently
favoured clinical applications for the treatment of deep seated tumours (>2 cm in
depth).
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Validation of the Effectiveness of mEHT Treatment

4.7.1

Introduction

mEHT has been clinically shown to be successful as a monotherapy as well as in complementing with radiation therapy and chemotherapy [SSS10]. Despite the positive
trials on mEHT, medical communities seem not to consider these results conclusive.
One of the challenges is to clearly define and measure the underlying physical principles in detail, of the mEHT treatment mechanism. Its mechanism heavily relies
on the physiological response of the cells and the work presented in this chapter
is designed to explicate the mEHT mechanism(s). Moreover, there are only a limited number of studies done in-vitro, thus it invites for more studies to be conducted.

In this study, clonogenic assays are used as a key experiment to help verify the effectiveness of mEHT treatment at the cellular level when combined with radiation,
to corroborate the previous findings from the mEHT research community [ASS09;
And+16; Yan+16]. Aggressive gliosarcoma and metastatic breast cancer cell lines
along with a non-cancerous cell line are utilised in this research. Experiments using a waterbath in this study represent conventional hyperthermia and is used as
reference. This will be the first study in mEHT to employ radiobiological clonogenic assay along with real time imaging to provide independent evidence on the
efficiency of the treatment. The effectiveness of mEHT is assessed both alone and
in combination with radiation therapy.
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4.7.2

Results

4.7.2.1

Validating Cell Membrane Damaged with Propidium Iodine (PI)
Staining

Figures 4.17 to 4.28 show the confocal images with propidium iodine (PI) staining
taken to test the selectivity of the mEHT on the cancer cell. PI is a membrane impermeant dye used to detect dead cells or cells with compromised cell membranes.
It is not permeant to live cells because their membrane are still intact but may freely
enter cells with compromised cell membranes.

Figure 4.17, Figure 4.21 and Figure 4.25 show that the selectivity effect of mEHT
is only observed in the 9L cell line at the 0 hour time point. That is, the damage
to the 9L cells membrane is clearly seen with the mEHT treated cells, and not in
water-bath treated cells. The 9L cells appear healthy in the images taken at 6, 12,
and 24 hours (see Figures 4.22, 4.23, and 4.24). This implies that repair may take
place shortly after the mEHT treatment. Conversely, damage induced by mEHT at
the 0 hour was not observed for the MCF-7 results (see Figure 4.25). As expected,
there was no damage observed to the MDCK cell line (see Figures 4.17 to 4.20) due
to the selectivity of mEHT as reported in the literature for other non-cancerous cell
lines [SSS10]. However, the common link observed in all 3 cell lines is the state of
the cells in the proceeding time points. All the cells look relatively healthy in both
treatment groups for all 3 cell lines at the time lapse images taken at 6, 12, and 24
hours (see Figures 4.18, 4.19, 4.20, 4.22, 4.23, 4.24, 4.26, 4.27, and 4.28).

4.7.2.2

Validating Cells Growth and their Rate of Change Period over
35 hours after Treatment

IncuCyte images were taken to assess the cells growth rate (proliferation) to investigate the proliferating rate of the cells pre-treated with mEHT compared to cells
pre-treated with the waterbath. The resulting data were normalised to the control
group (untreated cells) at the same time point for distinct comparison of the wa-

Figure 4.17: MDCK cells time-lapse images at 0-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.18: MDCK cells time-lapse images at 6-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.19: MDCK cells time-lapse images at 12-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.20: MDCK cells time-lapse images at 24-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.21: 9L cells time-lapse images at 0-hours performed a) without treatment (control set) b) with waterbath c) with mEHT. Cells
were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.22: 9L cells time-lapse images at 6-hours performed a) without treatment (control set) b) with waterbath c) with mEHT. Cells
were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.23: 9L cells time-lapse images at 12-hours performed a) without treatment (control set) b) with waterbath c) with mEHT. Cells
were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.24: 9L cells time-lapse images at 24-hours performed a) without treatment (control set) b) with waterbath c) with mEHT. Cells
were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.25: MCF-7 cells time-lapse images at 0-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.26: MCF-7 cells time-lapse images at 6-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.27: MCF-7 cells time-lapse images at 12-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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Figure 4.28: MCF-7 cells time-lapse images at 24-hours performed a) without treatment (control set) b) with waterbath c) with mEHT.
Cells were treated with waterbath and mEHT for 30 minutes. Propidium iodine dye (fluorescing in red) was added to the cells immediately
before taking the confocal microscope imaging. The assay was performed twice.
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terbath and mEHT curves. This experiment was carried out to investigate if the
apoptosis induced by mEHT affects the cell proliferation during the period shortly
after the treatment.

MDCK Cell Line

A slightly higher number of mEHT treated cells than the waterbath treated cells
were detected at the initial time point, as shown in Figure 4.29. Both treatment
groups displayed a decrease in their cell growth number (Figure 4.29) at a relatively
stable rate of change in their growth (Figure 4.30) from their initial time point up
to 12 hours. It should be stressed that the actual confluence values are not decreasing for the mEHT and waterbath treatment groups, but rather it is the value
normalised to their respective control group that is decreasing. Within this 12-hour
window, the response of the cell growth of both treatments are temporarily stagnant whilst their respective control groups confluence increases in a stable manner.
After 12 hours, the mEHT and waterbath treated cells displayed an active response
and this is evident in the more rapid fluctuation in the rate of cell growth (see Figure 4.30). Therefore, this results in the final growth curve converging to the same
number of cells relative to the control group (shown in Figure 4.29). This finding
showed no differentiation in the outcome of the mEHT treatment to the waterbath
on non-malignant MDCK cells.
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Figure 4.29: MDCK cell lines were plated in 36-well plates after mEHT or
waterbath treatment at the same starting density. After allowing cells to adhere
to the plate for 2 hours, cells were then monitored for confluence in an IncuCyte
imager over the timescale shown, and treated cells confluence relative to control is
graphed. The data was normalised to the control (untreated cells) for comparison
of the curves. Results from six replicated wells are shown. Error bars indicate ±
SEM.

Figure 4.30: MDCK cell lines were plated in 36-well plates after mEHT or
waterbath treatment at the same starting density. After allowing cells to adhere
to the plate for 2 hours, cells were then monitored for confluence in an IncuCyte
imager over the timescale shown, and the rate of change in treated cell confluence
relative to control is graphed. The data was normalised to the control (untreated
cells) for comparison of the curves. Results from six replicated wells are shown.
Error bars indicate ± SEM.
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9L Cell Line

A slightly lower number of mEHT treated cells compared to the waterbath treated
cells were recorded at the initial imaging time point (Figure 4.31). In the first 13
hours, cells of both treatments groups undergo a synchronised fluctuation of their
cell growth (Figure 4.31). As the data was normalised to the control group, the results indicate the change in the cell proliferating (growth) rate. The rate of change in
cell growth also increases in a near monotonic manner (Figure 4.32). The increasing
rate became exponential in the latter 10 hours, resulting in a convergent of the cells
growth number in both treatment groups as shown in (Figure 4.31). Even though
the proliferation is decreased just after the mEHT treatment, the results indicate
no added advantage for mEHT treatment alone on malignant 9L cells in the first 35
hours compared to that of waterbath treatment on the cells.

Figure 4.31: 9L cell lines were plated in 36-well plates after mEHT or waterbath
treatment at the same starting density. After allowing cells to adhere to the plate
for 2 hours, cells were then monitored for confluence in an IncuCyte imager over
the timescale shown, and treated cells confluence relative to control is graphed.
The data was normalised to the control (untreated cells) for comparison of the
curves. Results from six replicated wells are shown. Error bars indicate ± SEM.
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Figure 4.32: 9L cell lines were plated in 36-well plates after mEHT or waterbath
treatment at the same starting density. After allowing cells to adhere to the plate
for 2 hours, cells were then monitored for confluence in an IncuCyte imager over
the timescale shown, and the rate of change in treated cell confluence relative to
control is graphed. The data was normalised to the control (untreated cells) for
comparison of the curves. Results from six replicated wells are shown. Error bars
indicate ± SEM.

MCF-7 Cell Lines

Figure 4.33 and Figure 4.34 show an equivalent experiment on the MCF-7 cell line.
The data seems to be a combination of what was observed with the 9L and MDCK
cell lines. The mEHT and waterbath treated groups exhibited a similar trend for
confluence outcome for the MCF-7 cell line. That is, long-term behaviour showed
that the treated cells are converging to the control confluence value. This is evident
in the trend of the cell growth curves (see Figure 4.33) and rate of change in the
growth (see Figure 4.34). The convergence of the growth curve to the same number
of control cells was detected at 35 hours, as shown in Figure 4.33). Nonetheless,
the rate of change in the MCF-7 cell growth were relatively bound compared to
9L and MDCK (see Figure 4.32 and Figure 4.30). This is measured by the smaller
fluctuations around the normalised mark (Figure 4.34) in comparison to 9L (Figure 4.32) where the curve appeared to be monotonically increasing. This suggests
that MCF-7 cells may have a higher resistance to mEHT and waterbath treatments

CHAPTER 4. RESULTS AND DISCUSSIONS

129

than 9L cells over this time period.

As the mEHT treated cells provided a similar terminal confluence value (to the
control group and to the waterbath treated group) in the 35-hour time period for
both MCF-7 and 9L, this confirms the previous findings with the other two cell lines
that mEHT provides no increased cell death at the conclusion of this timeframe.

Figure 4.33: MCF-7 cell lines were plated in 36-well plates after mEHT or
waterbath treatment at the same starting density. After allowing cells to adhere
to the plate for 2 hours, cells were then monitored for confluence in an IncuCyte
imager over the timescale shown, and treated cells confluence relative to control is
graphed. The data was normalised to the control (untreated cells) for comparison
of the curves. Results from six replicated wells are shown. Error bars indicate ±
SEM.

4.7.2.3

Validating of mEHT Selectivity on Malignant Cells over 96 Hours

This section incorporates real-time imaging to analyse beyond the time points of the
results in Sections 4.7.2.1 and 4.7.2.2. Additionally, the non-malignant and malignant cells are co-cultured to investigate the selectivity of mEHT. As the co-cultured
cells began to adhere to the surface and proliferate, their structure became more
distinct which allowed for the distinguishing of the two cell lines in the IncuCyte
images. This was first observed at the 48-hour mark (see Figure 4.37 and Figure 4.42). The 72-hour and 96-hour images displayed a co-existence of both MDCK
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Figure 4.34: MCF-7 cell lines were plated in 36-well plates after mEHT or
waterbath treatment at the same starting density. After allowing cells to adhere
to the plate for 2 hours, cells were then monitored for confluence in an IncuCyte
imager over the timescale shown, and the rate of change in treated cell confluence
relative to control is graphed. The data was normalised to the control (untreated
cells) for comparison of the curves. Results from six replicated wells are shown.
Error bars indicate ± SEM.

and a particular malignant cell line in the control, waterbath and the mEHT treatment group. This is shown in Figures 4.38 and 4.39 for MDCK co-cultured with 9L,
and Figures 4.43 and 4.44 for MDCK co-cultured with MCF-7. The co-existence
demonstrated that the mEHT treatment did not demonstrate selectivity for the
malignant cells within this extended timeframe (refer to Figures 4.35 to 4.39 for
9L co-cultured with MDCK, and Figures 4.40 to 4.44 for MCF-7 co-cultured with
MDCK).

Figure 4.35: IncuCyte imaged of co-cultured of MDCK and 9L cells at 0-hour a) without treatment (control set) b) with waterbath c)
with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.36: IncuCyte imaged of co-cultured of MDCK and 9L cells at 24-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.37: IncuCyte imaged of co-cultured of MDCK and 9L cells at 48-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.38: IncuCyte imaged of co-cultured of MDCK and 9L cells at 72-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 72 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.39: IncuCyte imaged of co-cultured of MDCK and 9L cells at 96-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.

CHAPTER 4. RESULTS AND DISCUSSIONS
135

Figure 4.40: IncuCyte imaged of co-cultured of MDCK and MCF-7 cells at 0-hour a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.41: IncuCyte imaged of co-cultured of MDCK and MCF-7 cells at 24-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.42: IncuCyte imaged of co-cultured of MDCK and MCF-7 cells at 48-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.43: IncuCyte imaged of co-cultured of MDCK and MCF-7 cells at 72-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 72 hours. A representative example of the results from six replicated wells is shown.
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Figure 4.44: IncuCyte imaged of co-cultured of MDCK and MCF-7 cells at 96-hours a) without treatment (control set) b) with waterbath
c) with mEHT. Cells were treated with waterbath and mEHT for 30 minutes. The same cells density were seeded into 24-well plates and
imaged were taken every 24 hours. A representative example of the results from six replicated wells is shown.
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Validating Cells Death with Clonogenic Assay – Cells Survival
Fractions

The clonogenic assay results presented here, obtained after 15 doubling times of
each cell line investigated showed that the MDCK cells have a similar high survival
fraction for both the waterbath and mEHT treatment at (84 ± 7) % and (81 ±
4) % respectively. The results saw no therapeutic advantages of mEHT treatment
over the waterbath treatment on this non-malignant cell line. The 9L cells showed
a more apparent difference between the mEHT and waterbath treatments with a
survival percentage of (88 ± 16) % and (75 ± 18) % respectively. The MCF-7 cells
showed a greater apparent sensitivity to the waterbath treatment than the mEHT
treatment, bestowed a survival fraction of (50 ± 2) % and (61 ± 12) % respectively.

The difference in the survival fraction between the two malignant cell lines is within
their respective uncertainties for the mEHT treatment group (refer to the error bars
in Figure 4.45). However, if the trend for reduced proliferation in MCF-7 compared
to 9L cells is real, this may be due to mEHT and waterbath inducing a short-term
cell damage for 9L cells whereas it induced a more long-term impact on the cells
biological properties (e.g., capacity to divide and proliferate) in MCF-7 cells.

4.7.2.5

Validating Synergistic of mEHT with Radiation with Clonogenic
Assay

The survival fraction results for MDCK showed a marginal contribution of mEHT
pre-treatment when used in combination with a radiation dose of 5 Gy compared
to the case where radiation is used alone (see Figure 4.46). The survival fractions
obtained for radiation alone and its combination with mEHT were (5.4 ± 0.2) % and
(4.4 ± 0.2) % respectively. The survival fraction of 9L cells for radiation alone and
its combination with mEHT were (35 ± 1) % and (13 ± 1) % respectively. This is
a substantial decrease (Figure 4.47); indicating a supra-additive effect. The 9L cell
line is well known to be very resistant to radiation so this result makes it potentially

CHAPTER 4. RESULTS AND DISCUSSIONS

Figure 4.45: Normalised survival fractions of MDCK, 9L and MCF-7 cell lines
following 30-minutes exposure to treatment of mEHT or waterbath. Clonogenic
assay was performed on both untreated (control) and treated cells for the three
cell lines. The assay was performed at least 3 times. Errors bars represent the
SEM.
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clinically significant.

Despite the fact that MCF-7 showed a lower cell survival fraction than 9L when
treated with mEHT alone (see Figure 4.48), a similar outcome is not observed in
the mEHT combined with radiation treatment. This was expected because MCF-7
cells demonstrated resistance to mEHT as evident with the PI dye staining images
(see Figure 4.25, 4.26, 4.27, and 4.28) and the cells confluence rate of change (see
Figure 4.30). The survival fraction of MCF-7 cells under exposure to radiation alone
and mEHT treatment combined with radiation was (7 ± 1) and (6 ± 2) % respectively (Figure 4.48). The results yielded no enhancement of the combined mEHT
and radiation treatment on this radiosensitive malignant cell line.

Figure 4.46: Clonogenic cell survival assay were performed on MDCK cells
following 30 minutes exposure to mEHT treatment and 10MV irradiation at 5
Gy, with and without individual components of the combination. The assay was
performed twice. Errors bars represent the SEM.
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Figure 4.47: Clonogenic cell survival assay were performed on 9L cells following
30 minutes exposure to mEHT treatment and 10MV irradiation at 5 Gy, with
and without individual components of the combination. The assay was performed
twice. Errors bars represent the SEM.
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Figure 4.48: Clonogenic cell survival assay were performed on MCF-7 cells
following 30 minutes exposure to mEHT treatment and 10MV irradiation at 5
Gy, with and without individual components of the combination. The assay was
performed twice. Errors bars represent the SEM.
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Discussion

According to Hegyi et al., the mEHT treatment kills the malignant cells by apoptosis [HSS13]. Apoptosis happens through the external (membrane) signal path [HSS13].
The images of mEHT treated cells with PI staining demonstrate the damaged membranes at the immediate time point (i.e., at the 0 hour) on the aggressive 9L cells;
however, no additional membrane damage was evident for the MCF-7 cell line when
compared to the control without treatment. This suggests that the effect of mEHT
treatment is not universal across different tumours cell lines. This is consistent with
a reported set of results where it was shown that the mEHT treatment is effective
only on the most aggressive cells lines [SSS10]. However, this bias in which aggressive cell line it targets more effectively is not specified in the mEHT literature.
Additionally, the time lapse images taken for both 9L and MCF-7 after 0 hours indicate a different process that might be occurring within the cells as their membrane
integrity was maintained right up to the 24-hour test period. This is inconsistent
with the literature that demonstrated that mEHT destabilises the cell membrane
and increases its permeability [SSS10]. The observation in our results indicates a
repair mechanism may have occurred shortly after treatment in our real-time image
study (see Sections 4.7.2.1 to 4.7.2.3).

This hypothesis was supported by the IncuCyte proliferating cell curves over a period
of 35 hours after treatment (specifically, Section 4.7.2.2). For MCF-7, the fluctuation
for the rate of growth change in the curve also indicates a potential repair process
occurring (see Figure 6b). The rate of change in the cells proliferation increases
more rapidly towards the end of the 35-hour experiment period, which in this case
corresponds to the confluence value converging to the control cell number in the
mEHT treatment group as seen in Figure 6a. The marginal deviations in the rate
of change for cell growth seen in Figure 6b for MCF-7 did not occur for 9L, which
exhibited a near monotonic increase in the rate of cell growth change (see Figure
5b). Although this behaviour is vastly different to MCF-7, the ultimate outcome
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is the same: the cell confluence for both cell lines appear to be converging to the
control value of 1, which in turn is the resumption of normal cell growth. Thus for a
short-term timespan, there is no indication of an obvious advantage of mEHT as a
standalone treatment method. These results contradict the findings for the mEHT
cell damaging process, which has been repeatedly shown in numerous publications
to date [SSS10; ASS06; Meg+14]. The referred damage process is the permanent
damage in the cell morphology that in parallel caused the cells to undergo apoptosis
within the initial 48 hours after the mEHT treatment [Meg+14]. At the time frame
between 8 to 24 hours in the process is marked as the pivotal point where the cells
are committed to die [Meg+14; Van+01].

According to the literature, the time delay in the selection and the tumour destruction of mEHT is due to the programmed cell-death (apoptosis) [ASS06; ASS09]. It
has been repeatedly shown that the detection of apoptosis on the mEHT treated
cells is significantly greater than the waterbath hyperthermia treatment [And+16;
Yan+16]. Andocs et al. demonstrate this on U937 cell line using DNA fragmentation assay after 3 hours of treatment [And+16]. Yang et al. [Yan+16] demonstrated
this using FITC-conjugate Annexin V and propidium iodine reagents with different
types of malignant cells 24 hours after treatment, which include MCF-7 and also a
brain tumour cell line (U87MG) [Yan+16]. Our real-time imaging studies immediately post-treatment in Sections 4.7.2.1 to 4.7.2.3 are limited to assessing only the
physical outcome. It is customised to observe the potential occurrence of apoptosis. However, clonogenic assay is our selected tool for assessing programmed cell
death (i.e., beyond the possibility of cell reproduction). The results showed a lower
survival fraction for both malignant (9L and MCF-7) and non-malignant (MDCK)
cell lines which indicate that cells underwent apoptosis. Although the clonogenic
assay outcomes were positive in regards to inducing apoptosis for both malignant
cell lines, it also unfavourably targeted the benign cell line, which raises some doubts
on mEHTs selectivity characteristic.
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Experimental results reported by Szasz et al. on different cancerous cells co-cultured
with non-cancerous cells demonstrated a complete disappearance of malignant cells
by 24 hours in their most aggressive cell line, which is A431 squamous carcinoma
cell line [SSS10]. The study presented in this thesis did not show this same effect
on the aggressive 9L cell line that was co-cultured with MDCK cells for 96 hours as
seen in Figures 4.39. It is hypothesised here that the occurrence of a stronger repair
mechanism for 9L compared to the A431 cell line in this time span. The A431 cell
line is derived from epidermoid carcinoma in the human skin. Epidermoid carcinoma
cells are generally radiosensitive and chemosensitive [Hay04]. This suggests that the
repair mechanism for the A431 cell line may not be as highly active in comparison
to 9L. MCF-7 cells are less aggressive than 9L cells and thus the co-existence of
MCF-7 with MDCK cells result in Figure 6 is consistent with experimental results
reported by Szasz et al. for their non- aggressive malignant cell line [SSS10].

Although the supposed benefits of mEHT as a sole method of treatment are moderately observed, the greater potential of mEHT lies in multimodal therapies (chemotherapy and hyperthermia is the most common multimodal treatment) context in treating malignant cells. The initial damage on the 9L cells membrane (and potentially,
the cell overall) as seen in the PI staining image in Figure 4.21 immediately after
mEHT treatment (i.e., at the 0 hour) creates a window of opportunity to integrate
other treatment modalities. Thus, this marks the timing of our radiation to be near
immediately (i.e., 15 minutes) after the mEHT treatment. This also marks the first
instance of mEHTs selectivity being observed in this research. In corresponding to
the aforementioned observed initial damage of 9L cell membrane at the 0 hour, the
MDCK cell line is seen to be immune to the mEHT treatment. This is highlighted
by no evident difference between the control group and mEHT treated group on
MDCK (see Figure 4.17).
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For this study, the most significant sighting of selectivity from the mEHT treatment is observed when combined with 10 MV radiation in Section 4.7.2.5. The
observed selectivity is evident for the 9L cells SF results. MCF-7 cells are radiosensitive but the effectiveness of the combined treatment was not expected in this study
because the point of radiation (i.e., the timing) used was based on the results we
obtained for 9L and findings in literature [HO07]. In particular, the results from
Section 4.7.2.1 reflect this. It is possible that the absence of a lower survival fraction
in MCF-7 in this multimodal treatment is due to the time gap between applying
mEHT and radiation as data in Section 4.7.2.4 hints at a more long-term effect of
mEHT.

The 9L cells showed a supra-additive effect. It is hypothesized here that this is
caused by mEHT allowing for the initial damage to the cancerous cells, which in
turn allow for the free radicals generated from radiation to freely enter the cells and
effectively induce cell death (i.e., apoptosis). This is a significant result because 9L
is a type of tumour that is closely related to glioblastoma, the most fatal form of
brain cancer [Gho+07]. Additionally, there is currently no effective treatment for
this tumour type, not even in multimodal treatments. The experimental results find
mEHT to complement radiotherapy quite well. This is consistent with the literature
that shows that mEHT therapy is most effective when combined with conventional
treatments [SSS10; ASS09]. Hence, this proves to be a promising candidate of treatment for this type of cancer (i.e., glioblastoma).

All the mEHT literature results demonstrate only a short-term response in the cells
to the treatment in in vitro. The experiments and analyses conducted in this work
focused on the physical outcome of the mEHT treatment on the cells. The main component of this research is to assess the effectiveness of the mEHT treatment based
on the cells’ radiobiological “endpoint”, which has never been performed before.
The two main experimental methodologies employed in this research are real-time
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imaging and clonogenic assay. The aforementioned methodologies are less dependent on artefacts, as opposed to the methods utilised by other mEHT studies. The
advantage of this is that the results obtained here are interpreted more easily. In particular, with clonogenic assay as this is considered the gold standard in radiobiology.

In summary, no benefit of mEHT treatment alone was observed in this study. However, the combined mEHT treatment with radiation therapy on the most aggressive
and radioresistant malignant cells produced a significant increase in cell death. The
results show the potential of this combined treatment modality in some, but not
all, tumours cell lines. The most significant insight gained from the mEHT treatment is in its apparent potential to manipulate the cell growth rate. Specifically, on
the radioresistant 9L cell line (which is closely related to glioblastoma). This new
aspect of mEHT treatment shows promise as the cells growth rate is closely tied
to its radiosensitivity. Further study to support the results ascertained should be
performed to fully establish whether mEHT has a direct influence on the cell growth
rate. Additionally, the present work provides the first set of independent data that
is not based on external results or methods from other literature in the field. Future
research also could include the investigation and analysis of this combined treatment
method and the use of other cell lines.

4.7.3

Utilisation of Nanoparticles

4.7.3.1

Ceramic Nanoparticles Clonogenic Assay – Cells Survival Fractions

The previous findings of mEHT and Ta2 O5 NSPs treated cells are included in this
clonogenic survival fractions results for the combination to allow for direct comparison of the efficiency of the nanoparticles in the mEHT treatment. The presence
of Ta2 O5 NSPs in the mEHT treatment on the MDCK cells achieved a survival
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fraction of (91 ± 5) %. With a higher survival fraction than that of the mEHT
treated MDCK cells alone, this seems to imply that Ta2 O5 NSPs acted to protect
the cells from the mEHT treatment (Figure 4.49). This observation is also seen
in 9L and MCF-7 cells in their combined treatment of mEHT with Ta2 O5 NSPs,
achieving a survival fraction of (68 ± 12) % and (75 ± 3) % respectively (Figures
4.50 and 4.51). However, the survival fractions attained for the MDCK and MCF7 cells treated with Ta2 O5 NSPs and mEHT were higher than the Ta2 O5 NSPs
treated MDCK and MCF-7 cells alone (Figures 4.49 and 4.51). These results were
unexpected and will be discussed in section 4.7.3.6.

Figure 4.49: Normalised survival fractions of MDCK cell line cultured with
Ta2 O5 NSPs following 30 minutes exposure to treatment of mEHT or waterbath.
Clonogenic assay was performed on both untreated (control) and treated cells.
The assay was performed at least 3 times. Errors bars represent the SEM.

4.7.3.2

Combined Ceramic Nano-structured particles with mEHT and
Radiation – Clonogenic Assay

The results in this section are presented in logarithm to highlight any small differences in the survival fractions of the two different treatments. The survival fraction
of radiation alone and radiation combined with mEHT are included for direct comparison. In this combined mEHT with radiation and Ta2 O5 NSPs treatments, the
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Figure 4.50: Normalised survival fractions of 9L cell line cultured with Ta2 O5
NSPs following 30 minutes exposure to treatment of mEHT or waterbath. Clonogenic assay was performed on both untreated (control) and treated cells. The
assay was performed at least 3 times. Errors bars represent the SEM.

Figure 4.51: Normalised survival fractions of MCF-7 cell line cultured with
Ta2 O5 NSPs following 30 minutes exposure to treatment of mEHT or waterbath.
Clonogenic assay was performed on both untreated (control) and treated cells.
The assay was performed at least 3 times. Errors bars represent the SEM.
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results showed no benefit of Ta2 O5 NSPs contributing to the overall treatment on
the cells. The MDCK cells survival fraction for the radiation combined with Ta2 O5
NSPs and mEHT obtained a 10% decrease from the radiation combined with Ta2 O5
NSPs alone (Figure 4.52). Whilst, the 9L cells survival fraction for the radiation
combined with Ta2 O5 NSPs and mEHT obtained a 36% increase from the radiation
combined with Ta2 O5 NSPs alone (Figure 4.53).

Figure 4.52: Clonogenic cell survival assay were performed on MDCK cells
with/without Ta2 O5 NSPs following 30 minutes exposure to mEHT treatment
and 10MV irradiation at 5 Gy, with and without individual components combined
with radiation. The assay was performed twice. Errors bars represent the SEM.
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Figure 4.53: Clonogenic cell survival assay were performed on 9L cells
with/without Ta2 O5 NSPs following 30 minutes exposure to mEHT treatment
and 10MV irradiation at 5 Gy, with and without individual components combined with radiation. The assay was performed twice. Errors bars represent the
SEM.
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Metal Nanoparticles’ Cells Growth and their Rate of Change
Period over 35 Hours after Treatment

Similar to that observed in the incuCyte proliferating growth curve for the waterbath and mEHT treatment groups (Section 4.7.2.2), the Au NPs combined with
mEHT treated on the cells appear to follow the same trend and end-point after 35
hours of monitoring. A small variation in the proliferating cell growth numbers (i.e.
maximum being 5%) are detected at the initial time point between the Au NPs
combined with mEHT and their individual components (see Figures 4.54, 4.56,
and 4.58). Additionally, a relative stable rate of change in their proliferation growth
curves are observed in their initial 12 hours for the three treatment groups. After
this time point a visible fluctuation in the rate of change occurred for MDCK and
MCF-7 cell lines (see Figures 4.55 and 4.59) and a steep increase in the rate of
change occurred for 9L cell line (see Figure 4.57). These results demonstrate that
the impact of the Au NPs on the three cells lines when combined with mEHT is not
promising for long term treatment outcomes.

Figure 4.54: MDCK cell lines cultured with Au NPs were plated in 36-well
plates after mEHT or waterbath treatment at the same starting density. After
allowing cells to adhere to the plate for 2 hours, cells were then monitored for
confluence in an IncuCyte imager over the timescale shown, and treated cells
confluence relative to control is graphed. The data was normalised to the control
(untreated cells) for comparison of the curves. Results from six replicated wells
are shown. Error bars indicate ± SEM.
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Figure 4.55: MDCK cell lines cultured with Au NPs were plated in 36-well
plates after mEHT or waterbath treatment at the same starting density. After
allowing cells to adhere to the plate for 2 hours, cells were then monitored for
confluence in an IncuCyte imager over the timescale shown, and the rate of change
in treated cell confluence relative to control is graphed. The data was normalised
to the control (untreated cells) for comparison of the curves. Results from six
replicated wells are shown. Error bars indicate ± SEM.

Figure 4.56: 9L cell lines cultured with Au NPs were plated in 36-well plates
after mEHT or waterbath treatment at the same starting density. After allowing
cells to adhere to the plate for 2 hours, cells were then monitored for confluence
in an IncuCyte imager over the timescale shown, and treated cells confluence
relative to control is graphed. The data was normalised to the control (untreated
cells) for comparison of the curves. Results from six replicated wells are shown.
Error bars indicate ± SEM.
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Figure 4.57: 9L cell lines cultured with Au NPs were plated in 36-well plates
after mEHT or waterbath treatment at the same starting density. After allowing
cells to adhere to the plate for 2 hours, cells were then monitored for confluence in
an IncuCyte imager over the timescale shown, and the rate of change in treated
cell confluence relative to control is graphed. The data was normalised to the
control (untreated cells) for comparison of the curves. Results from six replicated
wells are shown. Error bars indicate ± SEM.

Figure 4.58: MCF-7 cell lines cultured with Au NPs were plated in 36-well
plates after mEHT or waterbath treatment at the same starting density. After
allowing cells to adhere to the plate for 2 hours, cells were then monitored for
confluence in an IncuCyte imager over the timescale shown, and treated cells
confluence relative to control is graphed. The data was normalised to the control
(untreated cells) for comparison of the curves. Results from six replicated wells
are shown. Error bars indicate ± SEM.
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Figure 4.59: MCF-7 cell lines cultured with Au NPs were plated in 36-well
plates after mEHT or waterbath treatment at the same starting density. After
allowing cells to adhere to the plate for 2 hours, cells were then monitored for
confluence in an IncuCyte imager over the timescale shown, and the rate of change
in treated cell confluence relative to control is graphed. The data was normalised
to the control (untreated cells) for comparison of the curves. Results from six
replicated wells are shown. Error bars indicate ± SEM.

4.7.3.4

Metal Nanoparticles Clonogenic Assay – Cells Survival Fractions

The mEHT and Au NPs treated cell results are included in this clonogenic survival
fraction results for the combination to allow for direct comparison of the efficiency
of the nanoparticles in the mEHT treatment. The survival fraction of the combined
Au NPs and mEHT treatment for the 9L and MCF-7 cells is (65 ± 9)% and (40 ±
1)% respectively. This result for MDCK is (72 ± 3)%. The survival fractions of the
combined Au NPs with mEHT are lower than the individual components achieved
for all the cells lines (see Figures 4.60, 4.61 and 4.62). This is an unfavourable
outcome for MDCK as it demonstrates that the healthy cells (i.e., MDCK) are more
susceptible to mEHT treatment when exposed to the Au NPs.

4.7.3.5

Combined Metal Nanoparticles with mEHT and Radiation –
Clonogenic Assay

The results in this section are presented in logarithm to highlight the small differences in the survival fractions of the different treatments groups. The trend of the
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Figure 4.60: Normalised survival fractions of MDCK cell line cultured with
Au NPs following 30 minutes exposure to treatment of mEHT or waterbath.
Clonogenic assay was performed on both untreated (control) and treated cells.
The assay was performed at least 3 times. Errors bars represent the SEM.

Figure 4.61: Normalised survival fractions of 9L cell line cultured with Au NPs
following 30 minutes exposure to treatment of mEHT or waterbath. Clonogenic
assay was performed on both untreated (control) and treated cells. The assay
was performed at least 3 times. Errors bars represent the SEM.
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Figure 4.62: Normalised survival fractions of MCF-7 cell line cultured with
Au NPs following 30 minutes exposure to treatment of mEHT or waterbath.
Clonogenic assay was performed on both untreated (control) and treated cells.
The assay was performed at least 3 times. Errors bars represent the SEM.

survival fractions of the combination of Au NPs with mEHT and radiation compared
to the combination of radiation and Au NPs alone for all the three cells lines are in
unity (see Figures 4.63, 4.64 and 4.65). That is, an increase in the survival fraction
compared to the combination of radiation and Au NPs for all the three cells lines.
For MDCK, this increase was found to be 41%. An increase of 23% and 42% for 9L
and MCF-7 cells respectively were obtained.

4.7.3.6

Discussion

The use of nanoparticles in the mEHT study was driven by the hope of gaining a better understanding of the mechanism of mEHT. The use of ceramic nano-structured
particle (i.e. Ta2 O5 NSPs) has demonstrated that the heat mechanism of mEHT may
be the dominant mechanism of cells killing. The higher survival fraction achieved
when the Ta2 O5 NSPs are present in the cultured cells during the mEHT treatment
implies that this ceramic nanoparticle must have shielded the cells from the mEHT
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Figure 4.63: Clonogenic cell survival assay were performed on MDCK cells
with/without Au NPs following 30 minutes exposure to mEHT treatment and
10MV irradiation at 5 Gy, with and without individual components of the combination. The assay was performed twice. Errors bars represent the SEM.
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Figure 4.64: Clonogenic cell survival assay were performed on MDCK cells
with/without Au NPs following 30 minutes exposure to mEHT treatment and
10MV irradiation at 5 Gy, with and without individual components of the combination. The assay was performed twice. Errors bars represent the SEM.
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Figure 4.65: Clonogenic cell survival assay were performed on MDCK cells
with/without Au NPs following 30 minutes exposure to mEHT treatment and
10MV irradiation at 5 Gy, with and without individual components of the combination. The assay was performed twice. Errors bars represent the SEM.
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heat generating process. The MDCK cells also achieved this higher survival fraction
due to the presence of the Ta2 O5 NSPs during the mEHT treatment. However, this
should not have been the case if mEHT does possess the selectivity capability to
not harm the healthy cells.

The higher survival fractions attained for the MDCK and MCF-7 cells treated with
combined Ta2 O5 NSPs and mEHT compared to the Ta2 O5 NSPs results alone were
unexpected. These results imply that the mEHT treatment minimised the Ta2 O5
NSPs toxicity to these cells. Based on our current knowledge of the mechanism of
the mEHT treatment, we propose an explanation. The heat generated by the mEHT
during treatment may have caused the nanoparticles to aggregate. The aggregation
means a decrease in reactivity of the particles with matter [BPR07]. This matter
can include cells. Considering that MDCK and MCF-7 cells were susceptible to the
toxicity of Ta2 O5 NSPs (Figures 4.49 and 4.51 respectively), it is plausible why the
impact of the decrease in reactivity of the nanoparticle were observed in these two
cells lines.

The non-favourable results obtained for the combination of Ta2 O5 NSPs and the
mEHT treatment and the combination of Ta2 O5 NSPs, mEHT and radiation paved
way to the possibility that the hyperthermia factor is the mEHT dominant component in the cell kill. For this reason, a metal nanoparticles (i.e. Au NPs) was
utilised to verify this. The Au NPs enhanced the cell killing in the mEHT treatment.
This is denoted in the decrease in the cell survival fractions compared to the mEHT
treatment alone on MDCK, 9L and MCF-7 cells lines. This implies that hyperthermia feature of the mEHT may be the dominant mechanism of treatment. However,
under the radiation field on the Au NPs and mEHT treated cells, the results were
unexpected. A higher survival fraction was attained for all the three tested cell
lines. This implies a different mechanism is taking place and that this study cannot
currently interpret or come to a definite conclusion on what influencing the mEHT
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treatment on the cells. Nevertheless, this study encourages more research to be
undertaken in the future to verify the mechanism of mEHT treatment.

Chapter 5
Conclusions and Future Directions
This thesis involves several studies related to research into multimodal treatment
approaches aiming, ultimately, to increase the radiation dose delivered to malignant
tumours. The central theme running through the thesis is an emphasis the impact
of high Z elements and compounds (relative to water) and radiotherapy radiation
environments.

One of the main focus studies was dedicated to examining the radiation sensitisation effect of 2 different high Z elements in the form of a drug compound and as
a nano-structured particle. Specifically, these high-Z elements were used in combination with the 5-FU drug on a study into the biological effect of X-rays on the
cancer cell line 9L (a rat gliosarcoma) model. Experiments were designed to quantify
the effect of these combinations and X-ray beam energies upon radiation-induced
damage using clonogenic survival analysis. This study demonstrated that there is
direct (observed in the cell SF curves) and indirect (observed in the cell SF curves)
evidence to suggest the different radiosensitisation enhancement effect of bromodeoxyuridine compounds (BrUdR) and tantalum pentoxide nanostructured particles
(Ta2 O5 NSPs) in combination with 5-FU in both kV and MV energies.

The mechanism of 5-FU as an indirect radiation sensitiser is elucidated to be due to
5-FU inhibiting cell repair as a result of the radiation damage. The results achieved
166
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for this combined model of a high-Z element with an anticancer drug provided a
reference data for the future exploration. In particular, this study also showed new
exciting potential for Ta2 O5 NSPs for implementation, and restored the potential for
BrUdR in combination with an anticancer drug in the field of radiation sensitisation
enhancement.

The synergistic effect achieved for the combination of BrUdR with 5-FU will allow for the transition into the subsequent in vivo model of experimentation. That
is, to determine whether the observed in vitro effects can translate into a useful in
vivo response. This will involve the use of a rat glioma model (e.g. Fischer 344
9L gliosarcoma-bearing rat). Specifically for in vivo, the combination of 5-FU and
BrUdR is ready for immediate implementation. Both of these agents have been
certified by the United States Food and Drug Administration (FDA). In order to
undertake in vivo experiments, two official ethics approvals are required. The first
is to characterise the mechanics of the delivery to the specimen (i.e., Fischer rats).
Some factors to consider include:
• Short-term toxicity on the specimen.
• Pathway for delivery of the agent to the brain. There are known issues related
with the drug delivery and the crossing of blood brain barrier (BBB). More
explicitly, the BBB often prevents drugs from efficiently reaching glioblastoma
cells, and therefore if this were to be undertaken then methods to enable drugs
to efficiently cross the BBB should be developed. However it should be noted
there has been some established work with the delivery via intraperitoneal
injection for the same specimen and cell line [Mil+13].
• The dynamics of delivering the agent through the chosen pathway also need
to be considered. For example, these include aspects like frequency (i.e., continuous or periodic), quantity of the agent (i.e., large or small quantity) and
the rate of delivery (i.e., fast or slow). These considerations are essential and
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can be quite costly if not evaluated thoroughly (e.g., excessive loading of the
specimen with foreign material). An assessment of the histology in real-time
is one tool that can be very informative when making these considerations.
The second ethical consideration is the introduction of radiation in conjunction with
the delivery of the combination of 5-FU and BrUdR.

The second main research aspect of this thesis investigated the potential validation of the mEHT treatment, particularly on its selectivity feature. With waterbath
(i.e., hyperthermia) treatment conducted in parallel in the experiment to provide a
reference data, the advantages of mEHT treatment are not evident on the MDCK,
9L and MCF-7 cell lines. The combined mEHT with radiation treatment witness
selectivity on the cancerous cells with an additive effect achieved for 9L cells. However, this positive result did not extend to the MCF-7 cells. To such a degree, this
study sees mEHT as an unreliable treatment modality in isolation, but worthy of
further study in the future as part of a multimodal therapy as highlighted below.

Futhermore, this research did not succeed in understanding the mEHT mechanism
of targeting cancerous cells. This targeting property was studied through the use of
ceramic and metal nanoparticles: Ta2 O5 NSPs and Au NPs respectively. This work
concludes, based on the results obtained, that heat (i.e., hyperthermia feature of the
mEHT treatment) is the main mechanism of targeting cells. However, under the
exposure of radiation, a different unidentified mechanism plays a larger role. This
resulted in the increase in the cell survival fractions in both normal and cancerous
cells when exposed to combination of mEHT, radiation and Au NPs. Thus, further
studies need to be conducted to investigate into the mEHT mechanism of targeting
cells as well as in vivo studies.
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